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Carcinogenesis usually consists of cancer initiation, promotion, and progression. Several 
tight junction claudin proteins have been identified as tumor suppressors or activators during 
cancer development. As apical proteins, tight junction claudins seal the apical sides of neighboring 
epithelial cells in regulating the transport of ions and fluids from the extracellular environment. 
However, claudin-7, which is believed to direct cell-matrix adhesion, has been found at the basal 
side of several human organs, including the lung. It has also been clinically reported that the low 
survival rate of lung cancer patients is closely associated with their low claudin-7 expression. The 
molecular mechanism of claudin-7 that regulates lung cancer progression is not clearly understood. 
In order to understand how claudin-7 is involved in lung carcinogenesis, this dissertation presents 
the molecular and cellular changes in human lung cancer cells upon the suppression of claudin-7 
expression to study how claudin-7 modulates lung cancer cell progression, including cell 
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CHAPTER I. INTRODUCTION 
 
A. Tight junction (TJ) and cell-cell communication 
Cellular communication is necessary to receive, generate, and share diverse cell signals 
among cells for cellular events, such as cell growth, differentiation, homeostasis, and migration 
(reviewed in (1)). For example, cells give signals to themselves or neighboring cells (autocrine or 
juxtacrine) and communicate with other cells from short or long distances (paracrine or endocrine) 
(reviewed in (1)). In the case of a skin injury, normally penetrable cell junctions are closed adjacent 
to the wound sites, but emerging cell junctions upon wound closure gain permeability, suggesting 
that the cell junction is involved in cell communication (2). This suggests that cell junctions 
support cell survival. Conversely, the disruption of cellular junction could result in dysfunction of 
cellular function. It has been found that cancer cells lack cell-cell communication (3, 4). Thus, 
studying the function of cell junctions is crucial to understand the mechanism of diseases, 
including cancers, at the cellular level.  
Cell junctions are divided into three categories depending on their role: occluding junctions, 
anchoring junctions, and communicating junctions (5-7). Occluding junctions are engaged in cell-
cell interaction. Tight junctions (TJs) are a type of occluding junction. They mainly act as a 
physical barrier by sealing the apical side of neighboring epithelial cells to prevent fluid and small 
molecules from moving in and out through intercellular space between the neighboring cells (8). 
TJs also regulate the permeability of selective ions between the neighboring epithelial cells (9). 
TJs consist of occludins, zonula occludens (ZOs), and claudins (10). While occludin and claudin 
proteins both have four transmembrane domains (10), claudin proteins have 24 family members 




paracellular activity; however, the cytosolic carboxyl tail has been shown to interact with various 
signals, such as regulatory proteins, tumor suppressors, and transcription factors (11). This 
suggests different roles of claudin proteins beyond their usual paracellular activity. 
Anchoring junctions help cells receive extracellular signals from extracellular 
environments, such as the extracellular matrix (ECM), through cell-matrix adhesion and respond 
to external environmental stimuli (12), and mechanical forces mediated by cell-cell adhesion and 
cell-matrix adhesion (13). Anchoring junctions build the resilient cellular structures between the 
cell membrane and ECM surface by connecting with either actin filaments or intermediate 
filaments (14, 15). For example, focal adhesion and hemidesmosome bind with transmembrane 
adhesion proteins, integrins, between the basal cell membrane and ECM (16). Integrins consist of 
18α and 8β subunits, which give rise to 24 heterodimeric transmembrane receptors (17). The 
numerous heterodimeric integrins bind and interact with their various corresponding ECM 
components, such as collagens, laminin, vitronectin, collagen, and fibronectin (reviewed in (18)), 
suggesting that integrins transmit many signals depending on the context of the ECM. 
Communicating junctions are also crucial to facilitate the intercellular communication 
between neighboring living cells (19). Gap junctions, a type of communicating junction, primarily 
consist of connexin subunits that create channels between neighboring cells (19). This allows 
adjacent cells to exchange cell signaling molecules, such as cyclic AMP, cyclic guanosine 
monophosphate (GMP), and inositol 1,4,5-triphosphoate (IP3), and inorganic ions, including Ca
2+ 
and Mg2+  (reviewed in (20)).  
Although each distinct junctional complex comes together to orchestrate both physical and 
cellular physiological function to ensure cell survival, as discussed above, recent studies have been 




the progression of diseases, including cancers (21-23).  
 
B. Claudin expression in human cancer cells 
Claudin expression has been connected to epithelial-mesenchymal transition (EMT) (24, 
25). A research study focusing on claudin-1 has revealed that the in vitro expression of transcription 
factors, including Snail and Slug, has repressed claudin-1 expression in kidney cell lines and 
disrupted the epithelial cellular structures, resulting in the loss of other cell junction proteins, such 
as ZO-1 and E-Cadherin (24). The authors also conducted a follow-up study using breast cancer 
cell lines and human breast cancer tumor samples to demonstrate the inverse relationship between 
Snail and Slug levels and claudin-1 expression, suggesting that claudin regulates cancer 
progression. 
In addition, claudin expression has been linked to cancer promotion and progression, 
including cell proliferation, migration, and invasion. The overexpression of claudin-6, -7, and -9 
in human gastric cancer cell lines has been shown to promote cell proliferation, migration, and 
invasion in vitro (26). In addition, epidermal growth factor (EGF)-induced claudin-3 
overexpression in colorectal cancer cell lines has been shown to increase cell proliferation, 
migration, and invasion abilities and anchorage-independent colony formation, showing the co-
regulation of claudin-3 and EGFR signaling in cancer cell proliferation (27). 
More importantly, claudins have also been closely related to cancer malignancy, such as 
cancer metastasis. The suppression of claudin-3 or claudin-4 expression in vitro in human 
carcinoma cell lines has been shown to increase cancer cell invasion in vitro, and the elevated 
metastatic ability was evidenced by micrometastatic lesions found in mouse lung tissues in vivo 




7 knockdown (KD) in ovarian cancer cell lines has decreased cell invasion (29). These findings 
suggest that the correlation between claudin expression and cancer malignancy, including 
migration and invasion, is specific to certain cancer cell types. 
Recent reports have revealed evidence that claudin proteins actively regulate cancer cell 
metastasis. The suppression of claudin-2 expression in vitro in human breast cancer cell lines has 
demonstrated that claudin-2 KD reduces breast cancer cell adhesion on claudin-2-expressing 
human hepatocytes (30). The author also demonstrated that disrupted expression in an extracellular 
loop of claudin-2 in breast cancer cell lines decreases the liver metastasis ability in the mouse liver 
in vivo (30), suggesting the role of claudin in regulating cancer cell adhesion and metastasis. 
Similarly, it has been clinically reported that the low survival rate of breast cancer patients is 
strongly associated with the high claudin-5 expression levels in the breast tissues of those patients 
(31). Furthermore, the same study has demonstrated that claudin-5 overexpression in human breast 
cancer cell lines increases cell proliferation, migration, and invasion in vitro, as evidenced by co-
immunoprecipitation results showing a physical linkage between claudin-5 and neuronal Wiskott–
Aldrich Syndrome protein (N-WASP), which suggests the function of claudin-5 in breast cancer 
cell metastasis. All these findings suggest that claudin differently regulates cancer metastasis in 
various cancer cell types.  
 
C. Interconnection between claudin-7 and human lung cancer 
Human lung cancer is the second leading cause of cancer patients’ death in the United 
States (32). About 85% of human lung cancer cases are categorized as non-small-cell lung cancer 
(NSCLC) types, while the remaining 15% are categorized as small-cell lung cancer (SCLC) types 




10% of lung cancer patients in the United States have never smoked (reviewed in (34)). Numerous 
molecular epidemiological research studies have been conducted to identify the potential causes 
of lung cancer incidences from genetic mutations, including p53, epidermal growth factor receptor 
tyrosine kinase (EGFR-TK), V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (K-ras), and 
deoxyribonucleic acid (DNA) methylation (reviewed in (34)). However, little has been discovered 
regarding the cellular or molecular mechanisms of lung cancer metastasis until recently. A clinical 
research team has recently found that low claudin-7 expression in lung cancer patients has a close 
association with the low survival rate of the patients five years after physical operations (35), 
suggesting that the loss of claudin-7 expression may promote the malignancy of lung tumors.  
 
D. Function of claudin-7 as basal membrane protein 
Unlike other TJ proteins localized at the apical side of epithelial cells, claudin-7 has been 
reported to be largely localized at the basolateral membrane of epithelial cells in many human and 
murine organ tissues, including the uterus, kidneys, murine mammary gland and murine mammary 
tumors, as well as intestines (36-39). It has been demonstrated that the loss of claudin-7 in intestine 
tissues in claudin-7 knockout mice leads to the disintegration of the intestinal mucosa and loss of 
α2 integrin (40), suggesting that claudin-7 stabilizes the cell-matrix attachment through integrins. 
More importantly, claudin-7 appears to be engaged in complex physiological activity. It has been 
shown that claudin-7 expression levels are decreased in rat uterine luminal epithelial cells during 
early pregnancy (36). Moreover, the expressions of focal adhesion proteins, including Talin and 
Paxillin, were decreased on day 1 of rat pregnancy (41). These studies on pregnant rats suggest 
that claudin-7 regulates focal adhesion during pregnancy. The findings discussed above suggest 




participates in physiological activity. 
 
E. Integrins in human cancers 
As briefly discussed above, claudin-7 and integrins seem to contribute to the establishment 
of cell-matrix adhesion. Integrin heterodimers are also located at the basal side of epithelial cells, 
and they bind with the ECM and transduce extracellular signals (17, 18, 42). Transformed cancer 
cells have resulted in changes in the composition of heterodimeric integrin expressions that have 
been found to regulate tumor cell proliferation, tumorigenesis, and metastasis in a variety of human 
cancers (43), suggesting different effects on carcinogenesis depending on integrin heterodimer and 
cancer cell type. In addition, integrins form integrin adhesion complexes, such as focal adhesion 
complexes, by recruiting Talin, Vinculin, and Focal Adhesion Kinase (FAK) (reviewed in (42)), 
and the integrin adhesion complexes facilitate actin polymerization and assemble with actin 
filaments (44). This suggests that integrin adhesion supports cell migration and invasion, which 
could support cancer metastasis. 
During cancer cell migration, integrin adhesion complexes extend their target ECM surface 
by extending actin filament skeletons and forming FAK through integrin clustering at the cell-
matrix interface (45, 46), while integrins also sense extracellular environmental signals and 
regulate intracellular signaling pathways, including MAPK and protein kinase B (Akt) pathways, 
for cell survival (47). Evidently, cell-matrix adhesion is necessary in cancer cell invasiveness, as 
integrins first form focal adhesion complexes and create invadopodia precursors by building actin 
filament–cytoskeletal protrusions (48). Once the invasive precursors are changed to matured 
invadopodia (49), the matured invadopodia extend the invasive actin cytoskeletal protrusions 




9 that degrade the target ECM basement membrane during cancer metastasis (51). For the cancer 
dissemination process through blood circulation, cancer cells need to detach from the ECM (52) 
and overcome anoikis, a type of cell apoptosis induced by the disruption of cell–ECM interaction 
(53). Integrins appear to be one of the major players in modulating cancer metastasis. 
 
F. Multiple stages of carcinogenesis 
Claudin has recently been highlighted for regulating carcinogenesis in human cancer cells, 
as previous reviews of human cancer cell research demonstrate the roles of several claudin proteins 
in controlling metastatic potential, including cancer cell proliferation, migration, and invasion. The 
stages of cancer development were initially proposed and investigated by Berenblum and Schubik 
in 1948 (54). The process of carcinogenesis has been thought to involve three main steps, including 
cancer initiation, promotion, and progression (Fig. I.1.) (54). In cancer initiation, exposure to 
carcinogens can give rise to spontaneous cellular changes by accumulating mutations in cellular 
genomes and creating reactive oxygen species (ROS) that damage mitochondrial and nuclear DNA 
(55). Little is currently known about how changes in claudin expression lead to such DNA damages 
in cancer initiation. 
In cancer promotion, the cells containing the initially mutated gene undergo clonal 
selection by propagating the population of daughter cells harboring the initial gene mutations, 
while they also possibly go through further gene mutations and chromosomal aberration that could 
establish tumor cells (54, 56). In the process, initially mutated cells are continuously transformed 
by accumulating additional mutations in proto-oncogenes, tumor suppressors, and DNA repair 
genes, all of which, in combination, lead to accelerated cell growth, suppressed cell apoptosis, and 




frequent mutations in genes such as p53 (tumor suppressor) and K-Ras (oncogene), as previously 
discussed in molecular epidemiology research identifying the causative gene mutations of lung 
cancer patients (34). We previously discussed that changes in the expression of several claudin 
proteins alters cancer cell proliferation, migration, invasion, and metastasis in various human 
cancer cells, suggesting that claudin modulates cancer promotion and progression.  
As tumor cells progress to develop more malignant subpopulations, they undergo 
angiogenesis and cell transformation, and develop metastatic potential (54). Rapidly growing 
tumor cells create tumor microenvironments where tumor cells need to receive more oxygen and 
nutrients for cell survival (57). Angiogenesis occurs to provide tumors with new vessels to supply 
enough nutrients and oxygen to keep up with the fast growth of tumor cells (57). In addition, tumor 
microenvironments increase the frequency of gene mutations, which also contributes to malignant 
transformations (58, 59). This could also promote tumor invasiveness. To initiate cancer metastasis, 
tumor cells need to overcome anoikis, a type of cell apoptosis induced by cell detachment from 
the ECM (60). A few claudin proteins have been documented to augment the resistance of tumor 
cells against anoikis. For example, in cell suspension, both colon cancer cell lines endogenously 
expressing claudin-1 and those exogenously expressing claudin-1 noticeably increased their 
resistance to cell death, and promoted downstream signaling for cancer cell survival, when 
compared to those cells with low claudin-1 expression (61), suggesting that claudin-1 expression 
suppresses anoikis in colon cancer cells.  
The aforementioned discussion suggests that changes in claudin expression may contribute 
to cancer cell initiation, promotion, and progression, which also alters cell signaling to determine 






G. Cancer metabolism 
Tumor microenvironments, which usually constitute low-oxygen and low-nutrient 
conditions, change cancer cell metabolism, which generates cellular energy to sustain rapid tumor 
cell growth (62). Under hypoxic conditions, hypoxia inducible factor (HIF) is stabilized, and it 
facilitates aerobic glycolysis to provide tumor cells with cellular energy necessary for rapid tumor 
growth (63). Aerobic glycolysis, or Warburg’s effect, expedites glucose uptake and its breakdown 
to pyruvate to produce lactate and two adenosine triphosphates (ATPs) while evading oxygen 
respiration by bypassing tricarboxylic acid (TCA) cycles. However, normally growing non-cancer 
cells convert pyruvate into acetyl coenzyme A (acetyl-CoA) that is completely oxidized by oxygen 
respiration to produce an additional 34 ATPs through TCA cycles in mitochondria (64). It has not 
been demonstrated whether claudin proteins modulate glucose metabolism in cancer cells to date. 
The above discussion suggests that the tumor microenvironment plays important roles in 
regulating glucose metabolism for cancer cell survival during cancer cell progression.  
 
H. Preliminary experiment 
H.1. In vivo metastatic lung tumor mouse model  
 Athymic mice were purchased from Charles River Laboratory (Wilmington, NC). 
Adherent HCC827 human epithelial lung cancer cells were chosen, as they were derived from 
human lung epithelial tissues of a female NSCLC patient. A total of 2×106 HCC827 claudin-7 
control or KD cells were suspended in 100 μl of phosphate buffer saline (PBS) and were 
intravenously administered via the lateral tail veins of 11 17–18-week-old mice. Changes in the 




4×106 HCC827 claudin-7 control or KD cells were administered to the respective experimental 
mice group, and their body weights were monitored for an additional 4 weeks. Finally, 8 weeks 
after the initial tail vein injections, all the mice were sacrificed. Their major organs, including lungs 
and livers, were removed for necropsy and fixed in 10% formalin solution for preservation. This 
experimental design was adopted and modified from (65) in communication with Dr. Hye-Jung 
Han at Berkeley National Laboratory. All experimental procedures using athymic mice subjects 
were performed according to the guidelines of the National Research Council Guide for the Care 
and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee 
at East Carolina University (AUP #A-172b) (See Appendix A).  
 
I. Preliminary experimental data that led to develop my Specific Aims 
I.1.HCC827 claudin-7 control or KD cells did not form metastatic tumors in mouse study. 
There were no symptoms of metastatic tumor formation such as shortness of breath and no 
significant reductions of body weight in either mouse group injected with HCC827 control or 
claudin-7 KD cells. Likewise, no metastatic nodules or micrometastatic lesions were found from 
the mice lungs and livers under a dissecting microscope upon necropsy (No publishable data 
available). 
  
J. Rationale for current study 
It has been clinically documented that lower claudin-7 expression has been closely 
correlated with a lower survival rate of lung cancer patients (35), suggesting that the loss of 
claudin-7 may aggravate the malignancy and invasiveness of lung cancers.  




human lung adenocarcinoma cancer cells (HCC827 claudin-7 KD cells) increases their cell 
proliferation but that claudin-7 overexpression in HCC827 claudin-7 KD cells reduces their cell 
proliferative rate to one comparable to that of HCC827 control cells (66). Cell cycle analysis has 
also confirmed that claudin-7 KD cells increase the dividing mitotic cell phase and reduce cell 
apoptosis, which was also evidenced by Western blot analysis showing a reduction in cleaved poly 
ADP ribose polymerase (PARP) and an increase in survivin (66). These results suggest that 
claudin-7 may play a role as a tumor suppressor. In contrast, the in vivo data obtained from mouse 
tumors subcutaneously injected with HCC827 caudin-7 KD cells in vivo showed an increase in 
both cell apoptotic factor (cleaved PARP) and anti-apoptotic factor (survivin), although the mouse 
tumor cells were much larger than the control cells (66). An in vitro cell culture system may allow 
HCC827 claudin-7 KD cells to freely access the oxygen and glucose that prevent cell apoptosis 
(66). However, little is known regarding how mouse tumor growth induced by HCC827 KD cells 
persists despite ongoing apoptotic activity in tumor microenvironments, where altered glucose 
metabolism could promote the survival of mouse tumors induced by HCC827 claudin-7 KD cells. 
Since HCC827 claudin-7 KD lung cancer cells demonstrated greatly elevated metastatic 
potential based on their predominant tumor growth and survival in vitro and in vivo as well as cell 
detachment from the ECM in vitro when compared to the claudin-7 control cells (66), the claudin-
7 KD cells were believed to have metastasized more predominantly than the control cells in vivo. 
However, our following in vivo metastatic mouse tumor study showed no significant change in the 
body weight of nude mice intravenously injected with either HCC827 claudin-7 control or KD 
cells up to a total of 8 weeks after the initial injection (Fig. I.2.), which was further confirmed by 
necropsy revealing no metastatic nodules or micrometastatic lesions in the tissues of sacrificed 




could not generate bone metastatic lesions, whereas the more malignant lung cancer cell line H522 
did in an in vivo mouse study, suggesting the possibility that using highly metastatic lung cancer 
cells with claudin-7 KD might metastasize more than those control cells in vivo. 
The above discussion supports the hypothesis that HCC827 claudin-7 KD cells have 
increased metastatic potential, such as accelerated cell proliferation and cell cycle progression, cell 
detachment from the ECM, and reduced cell apoptosis (66). However, no previous study has 
reported the claudin-7 KD phenotype in other human lung cancer cells. In addition, we are not 
aware of whether the tumor microenvironment mediates claudin-7 regulation in glucose 
metabolism to support cell survival, which could accelerate mouse tumor growth in vivo. Moreover, 
our previous study identified that claudin-7 formed a protein complex with β1 integrin and was 
partially co-localized with β1 integrin at the basolateral side of HCC827 control cells and that the 
expression of both proteins disappeared in HCC827 claudin-7 KD cells (66). These findings 
suggest the co-regulation of claudin-7 and β1 integrin in cell-matrix attachment. β1 integrin is a 
ubiquitously present integrin that is engaged in cell-matrix adhesion and cell motility. Claudin-7 
is also present at the basal side of epithelial tissues of several organs, as previously discussed (36-
39). However, little is known about how claudin-7 and β1 integrin cooperate with each other and 
co-regulate lung cancer cell migration, invasion, and attachment at the cell-matrix interface. 
Therefore, we propose that claudin-7 inhibits cell proliferation and serves as a tumor 
suppressor. KD of claudin-7 promotes cell survival under tumor microenvironment conditions. 
Claudin-7 cooperates with β1 integrin in regulating cell-matrix adhesion as well as cell migration, 





K. Specific aims 
Aim 1. Determine claudin-7 KD phenotype in regulating cell proliferation and cell 
attachment in H358 human lung cancer cell lines. 
Hypothesis: Claudin-7 KD in H358 human lung cancer cell lines increases cell proliferation and 
survival and reduces cell attachment, similar to the KD of HCC827 human lung cancer cells 
It has been previously shown that claudin-7 KD in HCC827 human lung cancer cell lines increases 
cell proliferation and cell survival while reducing cell attachment (66). However, it remains 
unanswered whether claudin-7 KD in other human lung cancer cell lines also gives rise to the same 
outcomes. H358 cells are human epithelial lung cancer cells showing basal localization of claudin-
7. We will treat H358 human lung cancer cells with the same lentiviral vector containing short 
hairpin RNA (shRNA) to suppress claudin-7 gene expression and then characterize the cellular 
phenotypic changes. We will focus on how the suppression of claudin-7 in the H358 cell lines 
modulates the cell proliferative rate, cell survival, and cell attachment and whether claudin-7 KD 
alters the protein expression of β1 integrin. Results from this aim will confirm whether claudin-7 
KD in other human lung cancer cell lines expressing endogenous claudin-7 gives rise to cellular 
phenotypes similar to our previous findings of increased cell proliferation and reduced cell-matrix 
attachment in HCC827 human lung cancer cell lines with claudin-7 KD.  
 
Aim 2. Characterize the role of β1 integrin in cell proliferation, migration, invasion, and 
attachment in HCC827 human lung cancer cells with claudin-7 KD. 
Hypothesis: The overexpression of β1 integrin in HCC827 claudin-7 KD cells improves cell 
migration, invasion, and attachment but not cell proliferation. 




protein complex localized at the basolateral side of HCC827 human lung cancer cells. It is not 
clear whether β1 integrin and claudin-7 regulate cellular phenotypes, including cell proliferation, 
migration, invasion, and attachment synergistically or independently. We will stably transfect a β1 
integrin complementary DNA (cDNA) vector into the claudin-7 KD of HCC827 human lung 
cancer cells to overexpress β1 integrin, and then, the cellular functions will be assayed using 
control and claudin-7 KD and β1 integrin-overexpressing claudin-7 KD cells. The results from this 
aim will clarify how β1 integrin and claudin-7 differentially regulate focal adhesion, cancer cell 
migration, and invasion in regulating cancer cell progression. 
 
Aim 3. Characterize the effect of claudin-7 KD on cancer cell survival via key genes 
regulating glucose metabolism. 
Hypothesis: Claudin-7 modulates the expression of key genes responsible for altering glucose 
metabolism in favor of cancer cell survival through GS kinase in tumor microenvironment 
conditions. 
Our recent in vivo metastatic study in nude mice (Fig. I.2) indicates that cancer cell lines derived 
from human primary tumor sites, such as HCC827, do not yet have high metastatic abilities, while 
cancer cell lines derived from metastatic tumor sites, such as H522, usually already have metastatic 
abilities. Therefore, the tumor microenvironment in vivo must provide the tumor cells with cues or 
signals to move them from the non-metastatic to the metastatic state. In addition, preliminary 
findings from Aim 1 indicate that nude mice injected with HCC827 human lung cancer cells with 
claudin-7 KD exhibit expedited tumor growth in terms of both size and weight. It is not clear how 
KD cell tumor growth persists in the presence of apoptotic factor (cleaved PARP), although anti-




to accelerated tumor cell growth at the tumor promotion stage under the tumor microenvironment. 
We will treat the claudin-7 KD of HCC827 human lung cancer cells under hypoxia and low glucose 
conditions in cell cultures to mimic the tumor microenvironment in vivo. This will determine 
whether claudin-7 KD lung cancer cells maintain the elevated levels of inhibitory phosphorylated 











Figure I.1 Carcinogenesis 
Carcinogenesis usually consists of cancer initiation, promotion, and progression. Cancer initiation 
occurs with the accumulation of mutations in nuclear and mitochondrial DNA by mutagens, such 
as ROS. In cancer promotion, the cells with the initial gene mutation are selectively propagated 
while chromosome aberration occurs, which could establish tumor cells. As the cancer cells 
progress, they are further transformed while adding more mutations on genes and surveilling 
genome integrity, cell proliferation, and DNA repair mechanisms. Alteration on these genes 










Figure I.2 In vivo metastatic study using athymic nude mice 
In total, 2×106 HCC827 control or claudin-7 KD cells were intravenously administered to 11 17–
18-week-old athymic mice through their lateral tail veins. Up to the first 4 weeks after the initial 
injections, there was no substantial reduction in body weight as a metastatic behavioral symptom 
from either mice group administered with claudin-7 control or KD cells. Thus, second injection of 
4×106 HCC827 claudin-7 control or KD cells were administered to the experimental mice group. 
Still, their body weights still revealed no remarkable changes during the second 4 weeks. After the 
total of 8 weeks, all the mice were sacrificed. Their major organs, including lungs and livers, were 
removed for necropsy and fixed in 10% formalin solution for preservation. No metastatic nodules 
or micrometastatic lesions were found from the mice lungs or livers under a dissecting microscope 
upon necropsy (Unpublished data). All experimental procedures using athymic mice subjects were 
performed according to the guidelines of the National Research Council Guide for the Care and 
Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee at 




CHAPTER II. A NON-TIGHT JUNCTION FUNCTION OF CLAUDIN-7  
INTERACTION WITH INTEGRIN SIGNALING IN SUPPRESSING LUNG CANCER 
CELL PROLIFERATION AND DETACHMENT 
 
This chapter is modified and reprinted from a journal article previously published on June 17, 2015, 
in Molecular Cancer, 14, 120. (2015) ((66), DOI:/10.1186/s12943-015-0387-0) under Creative 
Commons Attribution License 4.0 adapted by license agreement of BioMed Central and with 
permission of all other co-authors on the fair and appropriate use of the contents of this manuscript. 
As the first co-author of this manuscript, I revised and edited the manuscript, including the 
introduction, materials and methods, results, and discussion sections. I also conducted experiments 
to generate the revised figures and the “supplementary data” of this manuscript (See Appendix B). 
 
A. Summary 
Claudins are a family of TJ membrane proteins involved in a broad spectrum of human 
diseases, including cancer. Claudin-7 is a unique TJ membrane protein, in that it has a strong 
basolateral membrane distribution in epithelial cells and tissues. Therefore, this study aims to 
investigate the functional significance of this non-TJ localization of claudin-7 in human lung 
cancer cells. Previously, we found that HCC827 knockdown (KD) cells showed an increase in cell 
cycle and cell proliferation and a reduction in cell apoptosis, cell attachment, and β1 integrin 
expression. We also confirmed that claudin-7 formed a protein complex with β1 integrin and co-
localized with β1 integrin at the basolateral side of HCC827 control cells. However, their presence 




tumor growth in mice injected with HCC827 KD cells when compared to those injected with 
HCC827 control cells. In order to confirm whether the claudin-7 KD phenotype found in the 
HCC827 cell line is also found in other human lung cancer cell lines, we generated the claudin-7 
KD phenotype in NCI-H358 human lung cancer cell lines using the same lentiviral shRNA empty 
vector (H358 control cells) or shRNA vector targeting the claudin-7 gene (H358 KD cells). We 
reproduced the claudin-7 KD phenotype in NCI H358 cell lines showing an increase in cell 
proliferation and a reduction in cell apoptosis and cell attachment. Claudin-7 and β1 integrin were 
also partially co-localized of and formed a protein complex in H358 control cells. These similar 
findings further support the hypothesis that claudin-7 KD increases the cell proliferative rate and 
decreases cell attachment by interacting with β1 integrin.  
 
B. Introduction 
Lung cancer is the leading cause of cancer death in the United States, and the five-year 
survival rate is 15% (33). The majority of lung cancer evolves from lung epithelial lining the air 
passages. TJs are the most apical component of the junctional complex, and they provide the 
critical support of cell-cell adhesion in epithelial cells (68). The disruption of cell adhesion 
promotes cancer progression, invasion, and metastasis (11, 69). TJs serve as a barrier regulating 
the ions and small molecules through the paracellular pathway (70). Both the downregulation and 
upregulation of TJ proteins can alter the organized arrangement of TJ strands, allowing more 
nutrients and growth factors to cancerous cells, thus acquiring the cells with invasive behavior (71).  
Claudins are tetraspan proteins with molecular weights of 20–27 kDa (72), and they are 
the major structural and functional components of TJs. Abnormal expression and mislocalization 




analyzed the expression profile of different claudins in lung cancers and found that claudin-7 is 
downregulated in several types of lung cancers, including squamous cell carcinoma, at the 
messenger RNA (mRNA) level (77). Our previous study demonstrates that claudin-7 is strongly 
expressed in benign bronchial epithelial cells with a predominant cell-cell junction staining pattern, 
while it is either altered with discontinued weak expression or completely absent in lung cancers 
(78). However, the exact roles of claudin-7 in lung tumorigenesis are largely unknown.  
Although claudins are well-known apical TJ proteins, recent antibody-based studies have 
indicated that several claudins, including claudin-7, are not only localized at the apical TJs but also 
have a strong basolateral membrane distribution in the epithelial cells of various tissues (37, 40, 
79). These observations suggest that claudins could be involved in cell-matrix interactions. The 
principal proteins at the basolateral membrane responsible for anchoring cells to ECM proteins are 
integrins (80). Integrins are heterodimers with α and β subunits that play essential roles in cell 
attachment, survival, migration, and invasion (81, 82).  
In this study, we revalidated our previous finding from HCC827 claudin-7 KD cells (66), 
in that claudin-7 also co-localized and formed a protein complex with β1 integrin in H358 human 
lung cancer cells. The suppression of claudin-7 not only promoted cell proliferation but also 
disrupted the localization and downregulated the expression of β1 integrin at the protein level, 
resulting in severe defective cell attachment. Thus, our current findings further support the non-TJ 
function of claudin-7 in regulating cell attachment through β1 integrin in human lung cancer cells. 
 
C. Materials and methods 
C.1.Antibodies and reagents 




Biological Laboratories (Japan). The rabbit polyclonal anti-phospho-FAK (Cat. 3283S), anti-
phospho-extracellular signal-regulated kinase (ERK)1/2 (Cat. 9101S), anti-ERK 1/2 (Cat. 4695), 
and anti-cleaved PARP (Cat. 5626) were purchased from Cell Signaling Technology (Beverly, 
MA). The mouse monoclonal and the goat polyclonal anti-β1 integrin antibodies were purchased 
from BD Biosciences (Cat. 610467, Bedford, MA) and Santa Cruz Biotechnology (Cat. sc-6622, 
Santa Cruz, CA), respectively.  
 
C.2.Cancer cell culture and lentivirus shRNA KD of claudin-7 
Lung carcinoma cell line NCI-H358 (H358) was purchased from American Type Culture 
Collection (ATCC, Manassas, VA) and grown in RPMI 1640 culture medium containing 10% FBS, 
100 units/ml of penicillin, and 100 μg/ml streptomycin in a humidified air (5% CO2) atmosphere 
at 37oC. H358 cells were epithelial human lung cancer cells and expressed claudin-7 and β1 
integrin, similar to HCC827 human lung cancer cells.  Three lentivirus claudin-7 shRNA vectors 
were found as following nucleotide sequences (sequences #1: 5’-TTCCAAGGAGTATGTGTGA-
3’; #2: 5’-GGCTATGGGAGTGTCTAGA-3’; #3: 5’-TCCCTACCAACATTAAGTA-3’). The #2 
lentivirus claudin-7 shRNA vector was used to target claudin-7 in HCC827 cells (66). Likewise, 
the same #2 lentivirus claudin-7 shRNA vector was also introduced to suppress claudin-7 
expression of H358 cells and generate H358 claudin-7 KD cells. All the lentivirus vectors 
contained a GFP expression sequence and puromycin resistance gene (66). Thus, H358 cells 
transfected with an off-target shRNA were designated as H358 claudin-7 control cells and showed 
GFP expression as positive controls for successful lentivirus transfection. After 48 h incubation, 
successfully stably transfected cells were selected in 1 µg/ml puromycin. The stable transfects 




Similar to HCC827 KD cells, 80% of claudin-7 expression was also decreased in H358 KD cells 
when compared to the control cells. 
 
C.3.Cell number count and cell cycle analysis by flow cytometry 
A total of 5×103 H358 control or claudin-7 KD cells were seeded into each well of 24-well 
culture plates and then trypsinized on days 2, 4, and 6 after plating. A total of 1×105 6-micron 
AlignFlow Plus beads (Molecular Probes, Eugene, OR) were added to each sample, and the 
relative ratio of beads versus cells was obtained by the flow cytometer. The total cell number for 
each sample was then calculated.  
HCC827 control or claudin-7 KD cells untreated or treated with 5 μg/ml aphidicolin for 24 
h were harvested, washed with PBS, and fixed in 70% ethanol. Prior to analysis, cells were washed 
with PBS and then resuspended in the propidium iodide staining solution. Samples were analyzed 
on the flow cytometer.  
 
C.4.Immunofluorescence 
H358 control or claudin-7 KD cells grown on poly-D-lysine-coated glass coverslips (BD 
Biosciences) were fixed in 100% methanol for 8 min at -20oC and washed with PBS for 5 min 
before being blocked in 5% bovine serum albumin for 60 min at room temperature. After blocking, 
cells were incubated with primary antibody (dilution ratio 1:100). All antibodies were diluted in 
PBS containing 2.5% bovine serum albumin (BSA). After washing, cells were incubated with 
corresponding secondary anti-rabbit FITC-conjugated (Green) or anti-mouse Cy3-conjugated 
(Red) antibody (dilution ratio 1:400) for 45 min at room temperature. Staining cells only with 




mounted with ProLong Antifade Kit (Molecular Probes). Samples were photographed using a 
Zeiss Axiovert S100 or Zeiss LSM 510 laser confocal scanning microscope (Carl Zeiss Inc., 
Thornwood, NY) and analyzed by MetaMorph software (Molecular Devices, Sunnyvale, CA).  
 
C.5.Co-immunoprecipitation 
H358 control cells were washed three times with ice-cold PBS and then lysed in RIPA 
buffer. After centrifugation, the supernatants were incubated with either anti-claudin-7 or anti-β1 
integrin antibody at 4oC overnight. Protein A or protein G beads were then added to the mixture, 
followed by incubation at 4oC for 3 h. The beads were washed twice with RIPA buffer, once with 
high salt buffer (0.5 M NaCl), and once with Tris buffer (10mM Tris, pH 7.4). Bound proteins 
were eluted from the beads in SDS sample buffer and analyzed by Western blot. For the positive 
control, protein lysates were immunoprecipitated overnight with either primary anti-claudin-7 
rabbit antibody or anti-β1 integrin mouse antibody. Then, each lysate was subject to Western blot 
analysis and was successfully detected using the same primary anti-claudin-7 rabbit antibody or 
anti-β1 integrin mouse antibody at 22 kDa or 130 kDa in size, as shown in Fig. II.6.B.  
 
C.6.Process of mouse tumors harvested from in vivo tumor xenograft model 
An in vivo mouse tumor growth study was previously conducted. In brief, five-week-old 
male athymic nude mice were obtained from Charles River Laboratory and used for human tumor 
xenografts. A total of 2×106 HCC827 control or claudin-7 KD cells were suspended in the culture 
medium and injected subcutaneously into the left and right flanks of each nude mouse. All the 
mice were sacrificed 8 weeks after injection. The tumors were removed, weighed, and frozen at -




approved by East Carolina University. The frozen mouse tumors were ground using a pestle under 
liquid nitrogen and then lysed in RIPA buffer to prepare for Western blot analysis. 
 
C.7.SDS-PAGE and Western blot 
Whole cells were lysed in RIPA buffer (1% Triton-100, 0.5% deoxycholate, 0.2% sodium 
dodecyl sulfate, 150 mM sodium chloride, 2 mM ethylene diamine tetraacetic acid, 10 mM sodium 
pyrophosphate, 20 mM sodium fluoride) supplemented with a complete protease inhibitor cocktail 
tablet (Cat. 11836153001, Roche Diagnostics, Indianapolis, IN). After cell debris from the protein 
lysate was removed by centrifugation at 4°C, the protein concentration was measured using a 
PierceTM BCA Protein Assay Kit (Cat. 23225, Thermo Scientific, Grand Island, NY). Proteins (20 
μg per lane) were separated by SDS-PAGE gel, transferred to a nitrocellulose membrane 
(Amersham Protran 0.45 NC, GE Healthcare) by electrophoresis, and blocked and immuno-blotted 
with appropriate primary antibodies (dilution ratio 1:1000, see section C.1.) followed by 
peroxidase-conjugated secondary antibodies (dilution ratio 1:2500). Protein bands were visualized 
using an ECL detection reagent (GE Healthcare, Buckinghamshire, UK) and photographed using 
an X-ray film developer. 
 
C.8.Statistical analysis 
Statistical analysis was performed using Origin50 (OriginLab, MA) or SigmaPlot (SPSS 
Science, Chicago, IL) software. For each in vitro experiment, at least three independent 
experiments were performed. All data were recorded and expressed as means ± SE. The differences 
between two groups were analyzed using the unpaired Student’s t-test. All statistical tests were 





D.1.Increased cell proliferation in claudin-7 KD cells 
Our previous results confirmed the successful KD of claudin-7 using a #2 shRNA vector 
against claudin-7 gene expression in HCC827 cells (66). Using the same viral vector, we have also 
knocked down claudin-7 expression in NCI-H358 (H358) human lung cancer cells (Fig. II.1). 
As it has previously been found that claudin-7 KD in HCC827 cells increases the cell 
proliferative rate (66), we performed a cell counting experiment to investigate the cell growth rates 
of both H358 control and claudin-7 KD cells. After claudin-7 was knocked down in H358 cells, 
the cell proliferation rate increased. Starting from day 4, the number of claudin-7 KD cells was 
more than that of control cells, and the number of claudin-7 KD cells was almost twice that of 
control cells on day 6 (Fig. II.2.A). Thus, we confirmed that claudin-7 expression was associated 
with decreased cell proliferation.  
Then, we examined several proteins involved in cell proliferation, survival, and apoptosis 
by Western blot. Similar to the previous Western blot results from HCC827 claudin-7 KD cells 
(66), H358 claudin-7 KD cells showed increased levels of phospho-ERK1/2, phospho-Bcl-2, and 
survivin but decreased levels of cleaved PARP when compared to H358 control cells (Fig. II.2.B).  
To confirm our previous finding that cell apoptosis was reduced as indicated by decreased 
levels of cleaved PARP, we further investigated the reduced cell apoptosis of HCC827 claudin-7 
KD cells (66) by performing TUNEL (terminal deoxynucleotidyl transferase deoxyuridine 
triphosphate (dUTP) nick end labeling) staining in both HCC827 control and claudin-7 KD cells. 
Although the total population of apoptotic cells in both HCC827 control and claudin-7 KD cells 
was low, the claudin-7 KD cells showed a lower percentage of apoptotic cells than the control cells, 





D.2.Impaired cell attachment and decreased β1 integrin expression in H358 claudin-7 KD cells  
Our previous study demonstrated that claudin-7 KD in HCC827 human lung cancer cells 
showed defects in cell adhesion and attachment when compared to control cells. Thus, in this 
current study, we examined whether claudin-7 KD also weakened cell adhesion and attachment of 
H358 lung cancer cells. We found that H358 claudin-7 KD cells formed spheroidal colonies when 
plated on uncoated glass coverslips, whereas control cells adhered well after 2- and 5-days plating 
on the glass surface (Fig. II.4.A). Cell attachment assay results also revealed that only 15% of 
H358 KD cells were attached to the culture plate when compared to the control cells four h after 
plating on the culture plate (Fig. II.4.B). These results suggest that claudin-7 KD also results in 
losing cell adhesion and attachment, similar to the previous HCC827 claudin-7 KD study. 
The observed defect in cell attachment upon claudin-7 KD also indicates a non-TJ function 
of claudin-7 in the cell-matrix adhesion of human lung cancer cells. Among the various 
transmembrane protein domains, integrins are the principal receptors responsible for binding the 
cells to the ECM (81, 82). In our previous study, we found that β1 integrin was greatly decreased 
at both mRNA and protein levels, and the phosphorylation level of FAK was also substantially 
decreased at the protein level in HCC827 claudin-7 KD cells. Similarly, our previous claudin-7 
knockout mouse lung tissues also showed a reduction in signals of β1 integrin and phospho-FAK. 
All these results suggest that claudin-7 modulates β1 integrin and phospho-FAK.  
In order to rule out co-localization of claudin-7 with β1 integrin in HCC827 control cells 
due to bleed-through of immunofluorescent signals, single immunofluorescent staining of β1 
integrin or claudin-7 on HCC827 cells was performed (Figs. II.5.A and II.5.B). The images suggest 




HCC827 control lung cancer cells. Next, we determined whether the respective fluorescence 
signals of claudin-7 and β1 integrin were found by performing separate immunofluorescence 
staining with their corresponding anti-secondary antibody-only in HCC827 control cell culture. 
The weak auto-fluorescence images ruled out the possibility of nonspecific binding of either anti-
secondary antibody to HCC827 control lung cancer cells (Figs. II.5.A and II.5.B). 
Thus, we were able to perform double immunofluorescence staining using primary 
antibodies against claudin-7 and β1 integrin, and we confirmed their partial co-localization in 
H358 control cells, which disappeared in the H358 claudin-7 KD cells (Fig. II.6.A). Co-
immunoprecipitation experiments further demonstrated that claudin-7 interacted with β1 integrin 
and formed a protein complex in H358 control cells (Fig. II.6.B). These results were consistent 
with similar results previously shown in HCC827 control and KD cells (66), supporting the 
hypothesis that claudin-7 regulates β1 integrin expression. Western blot results also revealed that 
H358 claudin-7 KD cells decreased the levels of β1 integrin and phospho-FAK when compared to 
control cells (Fig. II.6.C), suggesting that claudin-7 KD in human lung cancer cells may result in 
the reduced focal adhesion.  
All these results demonstrated that claudin-7 KD in H358 human lung cancer cells reduces 
cell adhesion and cell attachment, which was also evidenced by the reduced expression of focal 
adhesion proteins, including β1 integrin and phospho-FAK (Fig. II.6.C). This is also consistent 
with those previously shown in HCC827 claudin-7 KD cells (66), supporting the hypothesis that 
claudin-7 regulates cell attachment through interaction with β1 integrin in human lung cancer cells.  
 
D.3.Claudin-7 suppressed tumor growth in vivo 




administering subcutaneous injections of HCC827 control or claudin-7 KD cells into the flanks of 
nude mice (66). The harvested mouse tumor tissues induced by the claudin-7 KD cells were 
significantly larger and heavier than those induced by the control cells, indicating that claudin-7 
inhibited the tumor growth in vivo.  
This current study further investigated the reason why HCC827 claudin-7 KD cells 
accelerated mouse tumor growth in vivo using Western blot analysis on previously harvested tumor 
tissues (66). The claudin-7 KD cell-induced mouse tumors significantly increased the protein 
expression levels of phospho-ERK1/2, survivin, and cleaved PARP when compared to those of 
control cell-induced tumors (Fig. II.7). This result demonstrated that mouse tumors with claudin-
7 KD cells substantially increased cell apoptosis and survival. This was in contrast to our previous 
Western blot analysis in an in vitro cell culture study showing a significant decrease in apoptosis 
(cleaved PARP) but an increase in anti-apoptosis (survivin) in HCC827 claudin-7 KD cells when 
compared to HCC827 claudin-7 control cells. This suggests that claudin-7 KD-induced mouse 
tumors support cell proliferation by inducing anti-apoptotic expression (survivin), which 
suppresses the cancer apoptosis initiated by apoptotic expression (cleaved PARP). 
 
E. Discussion 
In this study, we demonstrated that the KD of claudin-7 significantly reduced β1 integrin 
expression and its partial co-localization in NCI-H358 lung cancer cells (Figs. II.6 A and II.6 C). 
This result is comparable to our previous results from claudin-7 KD in both HCC827 lung cancer 
cells and breast cancer cell line T-47D displaying the severe cell-matrix adhesion defect (66). 
Confocal immunofluorescence microscopy and co-immunoprecipitation also revealed that 




control cells (66). These results suggest that the cell-matrix adhesion defect can be rescued by 
transfecting claudin-7 or β1 integrin into the claudin-7 KD cells in HCC827 and NCI-H358 lung 
cancer cells.  
Our previous findings on HCC827 claudin-7 KD cells also suggest that the KD of claudin-
7 in NCI-H358 cells promoted cell proliferation and cell cycle progression, which was also 
indicated by cell counting assays and Western blot analysis on H358 claudin-7 KD cells showing 
increased cell proliferation and reduced levels of apoptosis (cleaved PARP), as shown in Fig. 2. In 
addition, we further conducted a Western blot analysis using the harvested mouse tumors from our 
previous in vivo mouse tumor growth experiments based on HCC827 control and claudin-7 KD 
cells (66). Interestingly, while HCC827 claudin-7 KD cells previously demonstrated enlarged and 
heavier tumor growth in nude mice in vivo (66), apoptotic expression (cleaved PARP) was 
coincidentally highly expressed with an elevated anti-apoptotic factor (survivin). These results 
suggest that survivin suppresses downstream cascades of apoptotic signaling. It is also known that 
fast-growing tumors have a higher cell proliferation rate as well as a higher cell apoptosis rate due 
to the lack of nutrition and hypoxia within the tumor tissue (57, 83, 84). In the cell culture system, 
cancer cells have sufficient nutrition and oxygen. This could explain why a higher expression level 
of cleaved PARP was observed in claudin-7 KD cell-induced tumors (Fig. II.7), while claudin-7 
KD cells in culture previously exhibited a decreased level of cleaved PARP. Our current results 
suggest that claudin-7 could be a tumor suppressor in lung cancer, inhibiting tumor cell growth 
both in vitro and in vivo. 
Integrins are cell surface receptors that lack intrinsic tyrosine kinase activity. FAK is 
constitutively associated with β1 integrin of the integrin receptors. The binding of β1 integrin to 




site. It has been reported that claudin-2 facilitates cell-matrix adhesion by increasing the cell 
surface expression of α2β1 and α5β1-integrin complexes in breast cancer cells, promoting the 
formation of breast cancer liver metastases (85). Similar to HCC827 KD cells, we also found that 
the KD of claudin-7 reduced β1 integrin at protein levels and led to the disappearance of the protein 
complex formation of claudin-7 with β1 integrin in H358 KD cells. It remains largely unknown 
how claudins affect integrin expression. We were unable to detect claudin-7 in the nuclei of 
HCC827 or H358 cells by immunofluorescence staining (66); however, we cannot rule out the 
possibility that claudin-7 translocated into the nuclei at a level that was beyond the 
immunofluorescence detection sensitivity. Western blot analyses on nuclear extracts are needed to 
determine whether claudin-7 is present in nuclei and whether it can potentially affect β1 integrin 
transcriptional expression. On the other hand, claudin-7 could indirectly regulate β1 integrin 
transcription by regulating the transcription factors of β1 integrin, such as Pax6 (86), Hox D3 (87), 
hypoxia-inducible factor (HIF) (88), and c-Myc (89). One approach to investigate the potential 
transcription factors involved is to apply cDNA microarrays in the future.  
The suppression of claudin-7 was thought to not only disrupt cell-matrix adhesion but also 
promote higher cell proliferation. Thus, we previously investigated which of these two 
consequences was the primary effect of claudin-7 KD in HCC827 lung cancer cells (66). Frequent 
cell division can promote cell detachment. During mitosis, cells undergo large morphologic 
changes: They become detached, they form retraction fibers while the cell margin moves inward, 
and then they are finally rounded up and prepared for division (90). This indicates that cell-matrix 
detachment could be a consequence of rapid cell division. However, inhibiting the rate of cell cycle 
progression of HCC827 claudin-7 KD cells—either using drug treatment, such as aphidicolin or 




expression of the HCC827 KD cells (66). Type IV is the structural backbone of the basement 
membrane of several solid organs, including the lung, and it has the ability to interact with cell 
surface adhesion molecules, such as integrins (91). These results mentioned above suggest that 
cell attachment depends on both cell proliferation and β1 integrin levels; however, cell 
proliferation does not depend on cell attachment. Both the enhanced cell proliferation rate and the 
decreased β1 integrin level are the primary results of claudin-7 suppression in HCC827 and H358 
lung cancer cells.  
To conclude, in this study, we have discovered a novel function of claudin-7 as a basolateral 
protein in regulating cell proliferation and cell-matrix adhesion in lung cancer cells. This study 
extends our current understanding of the roles of claudins in carcinogenesis. Both claudins and 
integrins play essential regulatory roles in tumor proliferation, invasion, and metastasis. 
Understanding the molecular mechanisms of lung cancer cell-matrix adhesion could lead to the 
identification of novel therapeutic strategies to target tumor cells. This novel basolateral function 
of claudin-7 engaging β1 integrin in human lung cancer cells could provide a previously 
unidentified therapeutic target in the future.  
Our study suggests a tumor suppression role of claudin-7 in lung cancer growth and 
identifies a new function of claudin-7 in maintaining epithelial cell attachment through interaction 
with β1 integrin. 
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Figure II.1 KD of claudin-7 using #2 shRNA lentivirus construct against claudin-7 in H358 
lung cancer cells. 
A. Immunofluorescence images of H358 control and claudin-7 KD cells using anti-claudin-7 
antibody. The cells were fixed with 100% methanol. Scale Bar: 20 µm. B. Western blot shows that 











Figure II.2 Increased cell proliferation in H358 claudin-7 KD cells. 
A. In total, 5×103 H358 control and claudin-7 KD cells were seeded into 24-well plates. The cell 
numbers were counted 2, 4, and 6 days after the cells were plated. Claudin-7 KD cells displayed a 
significantly higher proliferation rate compared to the control cells on days 4 and 6. *P<0.05. B. 
Representative Western blots show an increased level of phospho-ERK1/2 and a decreased level 
of cleaved PARP in claudin-7 KD cells when compared to those of the control cells, while the total 











Figure II.3 Reduced cell apoptosis in HCC827 claudin-7 KD cells. 
A. HCC827 control and claudin-7 KD cells were fixed in 100% methanol and incubated with 10% 
BSA in PBS for 30 min at 37ºC before applying the TUNEL reaction mixture (Roche Diagnostics, 
Cat. 12156792910) to the cells for 1 h at 37ºC. The red signal indicates the apoptotic cells. The 
blue signal is the nuclear staining. Scale bar: 50 µm. B. The percentage of cell apoptosis was 
significantly lower in HCC827 claudin-7 KD cells compared to that of the control cells. Data were 










Figure II.4 Cell attachment defect in H358 claudin-7 KD cells. 
A. When cultured on uncoated glass coverslips, H358 claudin-7 KD cells formed spheroids on 
both 2-day (2d) and 5-day (5d) cultures, while the control cells were able to spread out and form a 
monolayer. Scale Bar: 30 µm. B. In total, 2×105 H358 control and KD cells were plated to each 
well of 24-well plates. After 4h, the unattached cells were washed off, and the attached cells were 
trypsinized and counted. Claudin-7 KD cells showed significantly reduced cell attachment 










Figure II.5 Single immunofluorescent staining of β1 integrin and claudin-7 on HCC827 cells. 
A. HCC827 control cells were grown on poly-D-lysine-coated glass coverslips and then fixed in 
100% methanol for 8 min at -20°C. After blocking, cells were incubated with mouse anti-β1 
integrin antibody for 1 h at room temperature. Coverslips were mounted with a ProLong Antifade 
Kit, and samples were photographed using a Zeiss Axiovert S100. Both low-density (top) and high-
density (bottom) cells were shown. Scale Bar: 15 µm. B. HCC827 control cells were treated in the 
same condition as in A., except that the primary antibody was the rabbit anti-claudin-7 antibody. 
The secondary antibodies were anti-mouse Cy3-conjugated antibody (Red color) and anti-rabbit 









Figure II.6 Reduced β1 integrin expression level in H358 claudin-7 KD cells. 
A. Double immunofluorescence staining of claudin-7 and β1 integrin in H358 control cells. Arrows 
in control cells indicate the partial co-localization of claudin-7 with β1 integrin. Cells were 
incubated with mouse anti-β1 integrin antibody and rabbit anti-claudin-7 antibody together 
(dilution 1:100) at room temperature for 1 h. Then, secondary antibodies against anti-mouse Cy3-
conjugated antibody (Red color) and anti-rabbit FITC-conjugated antibody (Green color) were 
used (dilution 1:400). Scale bar: 20 μm. B. Claudin-7 co-immunoprecipitated with β1 integrin. 
Control cells were lysed in RIPA buffer without SDS and immunoprecipitated with either anti-β1 
integrin or anti-claudin-7 antibody. The membrane was probed with either claudin-7 or β1 integrin. 
C. Western blots show that β1 integrin and phospho-FAK levels were decreased in H358 claudin-











Figure II.7 Apoptotic effect of claudin-7 on tumor growth in nude mice in vivo. 
Western blot results showed increased expression levels of phospho-ERK1/2, total ERK1/2, 
survivin, and cleaved PARP in claudin-7 KD cell-induced tumors when compared to those of 
control cell-induced tumors. For SDS-PAGE and Western blot analysis, 20 μg/μl of protein was 
loaded per well. Claudin-7 was probed to validate the effect of claudin-7 KD on mouse tumor 




CHAPTER III. CLAUDIN-7 MODULATES CELL-MATRIX ADHESION THAT 
CONTROLS CELL MIGRATION, INVASION, AND ATTACHMENT OF HUMAN 
LUNG CANCER CELLS 
 
A. Summary 
Claudins, a family of TJ proteins, play important roles in the epithelial barrier, selective 
ion transport, and cancer metastasis. The role of claudin-7 in cancer is unclear. However, a recent 
clinical study has shown that claudin-7 is associated with the survival of lung cancer patients after 
surgery. Our previous studies have shown the protein complex of β1 integrin and claudin-7 in 
HCC827 lung cancer cells. Moreover, in vitro claudin-7 KD reduced β1 integrin expression and 
increased cell proliferation, whereas claudin-7 re-overexpression in the KD cells decreased cell 
proliferation. Whether claudin-7 and β1 integrin synergistically or independently regulate cell 
proliferation and metastasis remains unclear. In this study, we found that β1 integrin 
overexpression in claudin-7 KD lung cancer cells did not reduce cell proliferation. However, β1 
integrin overexpressing cells migrated more effectively (*p < 0.05) in wound healing and cell 
invasion assays, and they were more adhesive (*p < 0.01) in cell attachment assays when compared 
to claudin-7 KD cells. This indicates that claudin-7 controls cell proliferation directly, while it 
regulates cell motility and attachment partially through β1 integrin. Additionally, claudin-7 
overexpression in claudin-7 KD cells resulted in a greater ability to attach to cell culture plate 
surfaces (*p < 0.05) and higher expression of focal adhesion proteins when compared to claudin-
7 non- KD control cells, further supporting the role of claudin-7 in cell motility and adhesion. 




insight into the roles of claudins in carcinogenesis and metastasis. 
 
B. Introduction 
Human lung cancer is the second leading cause of mortality in the United States (32). The 
lung expresses various TJ proteins depending on their compartments, including claudin-1, -2, -3, 
-5, -7, -8, and -18 (92). TJ proteins are one of the cellular junctional proteins located at the apical 
side of epithelial cells, and they regulate paracellular permeability between neighboring epithelial 
cells (93). One of the TJ proteins is the claudin family that consists of four transmembrane 
spanning proteins (93). Although the function of claudins as epithelial barriers for the maintenance 
of cell polarity and selective ion transport has been well established (94), their role in diseases, 
including cancer, is unclear. However, a possible link between TJs and metastasis has been recently 
demonstrated using human colon cancer cell lines in vitro (25, 95). The varying levels of claudin 
expression may be correlated to cancer progression (96). Additionally, claudin-5 has been shown 
to form a protein complex with ROCK and N-WASP and promote actin cytoskeletal movement in 
breast cancer cells (31), suggesting that TJ proteins are crucial for cancer cell motility.  
A recent clinical research study has shown that claudin-7 expression is associated with the 
survival of lung cancer patients after surgery (35), suggesting the role of claudin-7 in cancer 
progression. Results from our previous study demonstrated that claudin-7 KD (claudin-7 KD) in 
HCC827 human lung cancer cell lines increased cell proliferation and reduced β1 integrin 
expression and cell adhesion (66). Interestingly, claudin-7 was able to form a protein complex with 
β1 integrin and was partially co-localized at the basolateral membrane of HCC827 control cells 
(66). This suggests a possibility that claudin-7 and β1 integrin co-regulate cellular events, 




have shown the basal localization of claudin-7 in the epithelial cells of several organs, including 
the mammary gland, kidney, and uterus, suggesting the roles of claudin-7 in cell-matrix adhesion 
(36-38) and vesicle trafficking (38). In this study, we examined whether β1 integrin and claudin-7 
independently or synergistically functioned on cell proliferation, adhesion, migration, invasion, 
and attachment. Our results demonstrate that β1 integrin overexpression partially recovers the 
defective cell adhesion, migration, invasion, and attachment, but not cell proliferation, of claudin-
7 KD cells. 
 
C. Materials and methods 
C.1.Antibodies 
Rabbit polyclonal anti-phospho-Y397-FAK (Cat. 3283S), anti-FAK (Cat. 3285), anti-
phospho-Y118-Paxillin (Cat. 2541), and anti-GAPDH (Cat. 2118, clone 14C10) were purchased 
from Cell Signaling Technology. Goat polyclonal anti-β1 integrin antibody was obtained from 
Santa Cruz Biotechnology (Cat. sc-6622). Mouse monoclonal anti-Paxillin antibody (Cat. 610051) 
was obtained from BD Transduction Laboratories (San Jose, CA). The secondary anti-mouse (Cat. 
W4021) and anti-rabbit (Cat. W4011) antibodies tagged with HRP were purchased from Promega 
(Madison, WI). Rabbit polyclonal anti-claudin-7 antibody (Cat. 18875) was obtained from 
Immuno-Biological Laboratories, and mouse monoclonal anti-Myc (Cat. 46-0603) antibody was 
obtained from Invitrogen (Carlsbad, CA). 
 
C.2.Cell lines and reagents 
The HCC827 human NSCLC cell line was obtained from ATCC and cultured in RPMI-




fetal bovine serum (Cat. SH3007001, HyClone, Logan, UT, USA), 1% 10,000 U/ml penicillin, and 
10,000 μg/mL streptomycin (Cat. 15140-122, Gibco, Carlsbad, CA) in a 37°C, 5% CO2 humidified 
incubator. HCC 827 control or claudin-7 KD cell lines were previously established [1].  
 
C.3.Overexpression of β1 integrin or claudin-7 in claudin-7 KD cells 
In order to establish the stable transfection of β1 integrin in HCC827 KD cells (KD+b1 
cells), the β1 integrin cDNA vector (Transomics, Huntsville, AL) was digested at EcoRI and NotI 
restriction enzyme sites. The size of the β1 integrin cDNA insert was confirmed from DNA 
electrophoresis. The insert was gel-purified using a Gel Extraction kit (Cat. 28704, Qiagen, 
Valencia, CA) and then sub-cloned to a pcDNA3.1 vector at EcoRI and NotI restriction sites. After 
the pcDNA3.1-β1 integrin cDNA vector was transfected to HCC827 KD cells using Amaxa 
NucleofectorTM Kit V reagent (Cat. VCA-1003, Lonza, South Plainfield, NJ) by electroporation, 
the stably transfected cells were selected at 600 μg/ml Geneticin (G418) for 4 weeks. The stable 
transfectants were maintained in the culture medium containing 300 μg/ml G418. For the transient 
transfection, the pcDNA3.1-claudin-7-myc (mouse claudin-7 cDNA) vector was transfected to 
HCC827 KD and KD+b1 cell lines, and the transfectants were incubated and recovered overnight 
under an antibiotic-free medium. The transfectants were given fresh media the next day and used 
for the experiment within 72 h.  
 
C.4.SDS-PAGE and Western blot 
Whole cells were lysed in RIPA buffer (1% Triton-100, 0.5% deoxycholate, 0.2% sodium 
dodecyl sulfate, 150 mM sodium chloride, 2 mM ethylene diamine tetra-acetic acid, 10 mM 




cocktail tablet (Cat. 11836153001, Roche Diagnostics). After cell debris from the protein lysate 
was removed by centrifugation at 4°C, protein concentration was measured using a PierceTM BCA 
Protein Assay Kit (Cat. 23225, Thermo Scientific). Proteins (20 μg per lane) were separated by 
SDS-PAGE gel, transferred to the nitrocellulose membrane (Amersham Protran 0.45 NC, GE 
Healthcare, Piscataway, NJ) by electrophoresis, and blocked and immuno-blotted with appropriate 
primary antibodies (dilution ratio 1:1000) followed by peroxidase-conjugated secondary 
antibodies (dilution ratio 1:2500). Protein bands were visualized using ECL detection reagent (GE 
Healthcare) and photographed using an X-ray film developer. 
 
C.5.Cell proliferation counting assay 
A total of 2 × 104 HCC827 control, claudin-7 KD, and KD+b1 cells were seeded in 6-well 
plates, and the total cell numbers were counted after 2, 4, and 6 days by the trypan blue exclusion 
method using a CountessTM automated cell counter (Cat. C10227, Invitrogen).  
 
C.6.Cell attachment assay 
A total of 2 × 105 or 1 × 105 HCC827 control, claudin-7 KD, and KD+b1 cells were seeded 
in a 12-well plate or a 24-well plate, respectively, to assess the effect of β1 integrin or claudin-7 
overexpression on KD cell attachment, respectively. After 4 h incubation at 37°C in a 5% CO2 
humidified chamber, the culture medium was removed, and each well was washed briefly with 
PBS buffer to remove unattached cells. Then, the remaining attached cells were trypsinized and 
mixed with 6-micron AlignFlow Plus beads (Molecular Probes) at a concentration of 1 × 105 
beads/ml. Total cell numbers were calculated from the estimated relative ratio of beads to cells 





C.7.Wound healing migration assay 
The control, claudin-7 KD, and KD+b1 cells were plated in a 6-well plate until confluent. 
The cells were then cultured in serum-free media for 22 h. After creating a scratch using a pipet 
tip, serum-containing media was given, and the gap distance was photographed using an inverted 
Zeiss light microscope (Carl Zeiss Inc.) and analyzed by MetaMorph software (Molecular Devices, 
Sunnyvale, CA) at time points of 0, 3, 6, 12, and 24 h. The closed gap distance per time point was 
normalized to its respective initial gap distance at time point 0 per cell line.  
 
C.8.In vitro cell invasion assay 
A total of 2 × 105 HCC827 control, KD, and KD+b1 cells were suspended and seeded in 
500 μl of serum-free RPMI1640 on the membranes of the inner chamber in 6-well BD Matrigel 
plates (Cat. 354481). The outer chamber was also filled with serum-free media. After 24 h serum 
starvation, serum-containing culture media was added in the outer chamber. After 53 h incubation 
at 37°C in a 5% CO2 humidified incubator, the membranes from the inner chamber were scrubbed 
using a medium-wetted cotton swab. Counter cell staining was performed using modified protocols 
from the Hema-3 Stain Kit (Fisher Scientific, Pittsburgh, PA). In brief, the membranes were first 
fixed with fixative (Hema-3 Fixative) for 4 min, then stained in red color solution I (Hema-3 
Solution I) for 10 min (cytosol staining), and then stained in blue color solution II (Hema-3 
Solution II) for 10 min (nucleus staining). After two brief washes with de-ionized water, the 
membranes were quickly dried in air and mounted with glycerol on glass slides. Five areas per 
membrane sample were randomly selected under inverted light microscopy at 200 × magnification 




imaging software (Carl Zeiss Inc.). 
 
C.9.Statistical analysis  
All experiments were performed at least three times and data were presented as means ± 
standard error of means. Student’s t-test was performed to compare samples from two cell lines, 
and a one-way analysis of variance (ANOVA) was performed in samples from three cell lines 
followed by a post-hoc comparison using IBM SPSS software. We considered differences 
statistically significant when *p < 0.05. 
 
D. Results 
D.1.β1 integrin overexpression did not alter the cell proliferative rate of claudin-7 KD cells  
Our previous study showed that HCC827 claudin-7 KD lung cancer cells increased the cell 
proliferative rate, decreased the expression of a variety of ECM components (including collagen 
IV and cell adhesion proteins, such as β1 integrin), and displayed reduced cell adhesion compared 
to HCC827 cells with no claudin-7 KD (claudin-7 control cells) (66). Although the reduced cell 
adhesion and ECM components appeared to accelerate the proliferative rate of the KD cells, 
supplementing the KD cells with collagen IV improved cell attachment but did not change the cell 
hyper-proliferative phenotype (66). This suggests that cell adhesion proteins such as β1 integrin 
may be more important in regulating cell adhesion and migration, as protein complexes of claudin-
7 and β1 integrin were partially co-localized at the basolateral membrane (66). β1 integrin can 
form heterodimers with various α integrin partners, and it regulates cell proliferation and cell-
matrix attachment and binds to the actin cytoskeleton for cell motility (97). This suggests that the 




comparable to that of control cells. Thus, we transfected β1 integrin cDNA into the claudin-7 KD 
cells (KD+b1) to see whether β1 integrin overexpression decreased the KD cell hyper-proliferative 
rate. Cell numbers were expressed as means ± standard error of means. The cell numbers of the 
KD and KD+b1 cells were not different on day 4 (8.1×104 ± 1.7×103 vs. 7.4×104 ± 1.0×104) or day 
6 (1.5×105 ± 1.2×104 vs. 1.5×105 ± 1.8×104). However, the numbers of KD and KD+b1 cells were 
far more than those of control cells on day 6 (6.8×104 ± 4.3×103) (*p < 0.05) (Fig. III.1). This result 
showed that β1 integrin expression did not rescue the claudin-7 KD cell hyper-proliferative 
phenotype, suggesting that β1 integrin may not be directly involved in regulating the cell 
proliferation of claudin-7 KD cells. 
 
D.2.β1 integrin overexpression partially recovered the cell adhesion of claudin-7 KD cells 
Although claudin-7 KD cells increased the cell proliferative rate, they exhibited a reduction 
in cell adhesion and β1 integrin expression (66). In addition, β1 integrin and claudin-7 formed a 
protein complex, and they were co-localized at the basolateral membrane of HCC827 control cells 
(66). This suggests the possibility of claudin-7 regulation of cell adhesion through β1 integrin. 
Therefore, we overexpressed β1 integrin in the claudin-7 KD cells to examine whether claudin-7-
regulated cell adhesion occurs through β1 integrin. Similar to control cells, KD+b1 cells also 
formed a monolayer on glass coverslips, although a spheroidal clump remained, indicating 
incomplete cell spreading, whereas claudin-7 KD cells displayed spheroidal colonies only, as 
previously reported (Fig. III.2.A) (66). Likewise, KD+b1 cell layers around the scratch site were 
less stripped off than claudin-7 KD cell layers, similar to control cell layers when using pipet tips 
(Fig. III.2.B). 




ability of cell attachment to the dish in the claudin-7 KD cells.  
 
D.3.β1 integrin overexpression enhanced cell migration and invasion ability of claudin-7 KD cells 
We showed that β1 integrin overexpression partially recovered the cell adhesion of claudin-
7 KD cells, but the effects of claudin-7 via β1 integrin on cell motility have not been studied before. 
Thus, we next examined whether β1 integrin overexpression recovered the reduced cell migration 
and invasion of claudin-7 KD cells using wound healing and cell Matrigel invasion assays, 
respectively. Wound healing assays showed that KD+b1 cells migrated faster than claudin-7 KD 
cells (*p < 0.05) but slower than control cells (*p < 0.05) at all time points. At 24 h, control cells 
filled up the initial gap by 82.3% ± 6.8%, while KD cells and KD+b1 cells filled up the initial gap 
by 50.2% ± 1.9% and 59.3% ± 3.0%, respectively (Figs. III.3.A and III.3.B). This indicates that 
β1 integrin partially compensates for the defect in KD cell migration caused by claudin-7 KD. 
Additionally, KD+b1 cells invaded more efficiently than claudin-7 KD cells (*p < 0.05) but less 
efficiently than control cells (*p < 0.01) (Figs. III.4.A and III.4.B). The average numbers of 
invading control cells were 29.2 ± 2.9, while those of KD and KD+b1 cells were 6.6 ± 0.5 and 
17.5 ± 2.5, respectively. This indicates that β1 integrin overexpression also partly recovers the 
defective cell invasiveness of KD cells.  
 
D.4.β1 integrin overexpression partially restored defective cell attachment of claudin-7 KD cells 
β1 integrin overexpression significantly improved the cell adhesion of claudin-7 KD cells, 
indicating that claudin-7 may result in an increase in cell-matrix attachment via β1 integrin at cell-
matrix interactions. Thus, we first investigated whether the overexpression of β1 integrin 




The number of KD+b1 cells that remained attached was significantly higher than that of claudin-
7 KD cells (*p < 0.01) but significantly lower than that of control cells (*p < 0.001) in the cell 
attachment assay (Fig. III.5.A). This indicates that β1 integrin overexpression partially restores the 
defect in the cell attachment of claudin-7 KD cells.  
In order to fully restore the defective KD cell attachment, we transiently transfected 
claudin-7 cDNA-containing Myc-tag into the KD cells to generate KD+cldn7 cells. The cell 
attachment results showed that the number of KD+cldn7 cells that remained attached was 
significantly higher than that of control cells (*p < 0.05) and claudin-7 KD cells (*p < 0.01) (Fig. 
III.5.B), indicating that overexpression of claudin-7 strengthened the cell-matrix attachment of the 
KD cells far better. Western blot analysis confirmed the overexpression of β1 integrin or claudin-
7 in KD cells (Fig. III.5.C). Although β1 integrin expression moderately increased the level of 
phospho-FAK in KD cells compared to that of the control cells, claudin-7 overexpression greatly 
elevated the expression levels of phospho-FAK, phospho-Paxillin, as well as β1 integrin in 
KD+cldn7 cells when compared to control cells (Fig. III.5.C). This result indicates that both β1 
integrin and claudin-7 synergistically support cell attachment, although claudin-7 appears to have 
a greater effect than β1 integrin.  
Taken together, these results suggest that β1 integrin overexpression in claudin-7 KD cells 
partially recovered the control cell adhesion, migration, and invasion but not cell proliferation. 
 
E. Discussion 
In this study, we noticed that β1 integrin overexpression in claudin-7 KD cells did not lead 
to claudin-7 expression, but claudin-7 overexpression in KD cells sufficiently revived β1 integrin 




complex co-localized at the basolateral membrane of HCC827 control cells (66). These results 
suggest that claudin-7 and β1 integrin may cooperate with each other, although claudin-7 seems to 
have a greater ability to control cellular phenotypes. For example, β1 integrin overexpression did 
not change the hyper-proliferative rate of claudin-7 KD cells. However, claudin-7 overexpression 
in KD cells reduced the cell proliferation rate (66). This indicates that claudin-7 may enable β1 
integrin at the basolateral membrane to properly receive signaling from the ECM to control lung 
cancer cell proliferation. This does not align with the current dogma of β1 integrin signaling that 
regulates cell proliferation and survival (98). For example, deletion of β1 integrin reduces the cell 
proliferation of the mammary gland at the cellular level (99, 100). At the organ level, β1 integrin-
knockout mice die before birth (99) probably due to the absence of β1 integrin survival signaling. 
In contrast, our claudin-7 KD cells suppressed β1 integrin expression but accelerated cell 
proliferation (Fig. III.1). Other β integrins could compensate for the lack of β1 integrin signaling 
to promote cell proliferation. In a breast cancer cell study, β3 integrin signaling was activated to 
increase cell proliferation and invasion when β1 integrin was suppressed (101). Future 
investigation is thus warranted to clarify the compensatory effect of other β integrins on claudin-7 
KD cells. 
Second, claudin-7 also synergistically collaborates with β1 integrin to control cell adhesion, 
migration, invasion, and attachment. We demonstrated that KD+b1 cells have improved cell-
matrix adhesion when compared to claudin-7 KD cells (Fig. III.2.B), indicating that β1 integrin 
overexpression supports the role of claudin-7 in cell-matrix adhesion through the basolateral 
membrane of KD cells. However, KD+b1 cells still showed a reduction in the rate of cell migration 
when compared to control cells. Cell migration requires proper cell-matrix adhesion; focal 




maintains an extended actin cytoskeletal protrusion in the direction of cell migration, and it is 
further stabilized by nascent adhesion along with lamellipodia at the leading cell edge (45, 46). 
The consequentially skewed cell shape accumulates contractile force, which eventually drives cell 
migration when rear cell adhesion is released (45, 46). When claudin-7 is low in quantity, focal 
adhesion through the basolateral membrane may not be properly established, inhibiting the 
subsequent process of cell migration. This suggests that claudin-7 cooperatively regulates cell 
migration via β1 integrin. 
Similar to the cell migration process, cell-matrix adhesion is also essential in cell 
invasiveness: Integrins form focal adhesion complexes, which results in the creation of an actin 
cytoskeletal protrusion as an invadopodia precursor (48). In addition, β1 integrin recruits integrin-
linked kinase (ILK) that transforms the invadopodia precursor into adhesion ring-containing 
matured invadopodia (49), which allows the extension of the actin cytoskeletal protrusions and 
activates ECM degradation activity (48-50). The low amount of claudin-7 may reduce the number 
of focal adhesion complexes and prevent further processes of cell invasiveness. Although β1 
integrin overexpression in KD+b1 cells may increase the amount of integrin clustering, the low 
quantity of claudin-7 in the KD+b1 cells may not effectively anchor the β1 integrins through the 
basolateral membrane and thus make it unable to fully recover the intensity of focal adhesion and 
degradation enzyme activity as it does in the control cells.  
Likewise, cell-matrix adhesion is crucial in cell-matrix attachment. Claudin-7 
overexpression in claudin-7 KD cells (KD+cldn7) recovers cell attachment ability at a far higher 
level than that of control cells. The increased cell attachment in claudin-7 overexpression is due to 
the excessive level of focal adhesion proteins confirmed by Western blot results, suggesting that 




the target ECM surface than that of control cells. It is likely that claudin-7 overexpression also 
inhibits cell migration and invasion by creating excessive cell-matrix adhesion, which could also 
result in the reduced metastatic potential of lung cancer cells (78). However, we were unable to 
test the metastatic possibility in vivo due to the intrinsically poor metastatic potential of HCC827 
cell lines (67). Future experiments on whether claudin-7 overexpression inhibits cancer metastasis 
using metastatic lung cancer cell lines in vivo will distinguish the different roles of β1 integrin and 
claudin-7 in coordinating cancer cell motilities.  
Interestingly, claudin-7 proteins may serve as anchoring domains to recruit other cell 
adhesion proteins at cell membranes, as previously shown for β1 integrin (66) as well as other cell 
adhesion proteins, including cluster of differentiation 44 (CD44) and epithelial cell adhesion 
molecule (EpCAM) (102, 103), all of which could contribute to the overall cell-matrix adhesion 
of lung cancer cells. This may explain, in part, why β1 integrin overexpression in claudin-7 KD 
cells did not fully recover the cell-matrix adhesion, migration, invasion, and attachment.  
The ability of claudin-7 interaction with β1 integrin to establish cell-matrix adhesion 
appears to be important to understand the molecular mechanism of Human Immunodeficiency 
Virus (HIV) infection. It has been reported that HIV infected a cluster of differentiation 4 (CD4)(-)) 
T cell subpopulation when the claudin-7 gene was introduced to the HIV particles in vitro (104). 
However, it remained unclear whether surface ligands in the CD4(-) T cells could interact with 
claudin-7 of the viral particle. Recently, it has also been reported that peripheral blood lymphocytes 
from normal patients show the high-level β1 integrin (CD29) surface marker in 66% of the CD4(-) 
T cell subpopulation (105). This suggests that claudin-7 proteins in the HIV-1 viral coat may 
interact with the CD29 present in the host CD4(-) T cells, which could establish mutual membrane 




CD4(-) T cells.  
In this report, we conclude that claudin-7 functions as a cell adhesion protein that 
modulates cell-matrix adhesion and regulates cellular processes, including lung cancer cell 
migration, invasion, and attachment. 
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Figure III.1 Exogenous β1 integrin expression did not reduce hyper-proliferation of claudin-
7 KD cells. 
A total of 2 × 104 control, KD, and KD+b1 cells were seeded in 12-well plates, and the cell numbers 
were counted for each sample 2, 4, and 6 days after the initial cell culture date. KD+b1 cells did 
not show any significant change in cell proliferation rate when compared to claudin-7 KD cells 
during the entire cell growth period. Both KD and KD+b1 cells showed significantly higher 
proliferating cell numbers when compared to the control cells on day 6 (*p < 0.05). At least three 










Figure III.2 Exogenous β1 integrin expression improved cell-matrix adhesion of claudin-7 
KD cells. 
A. Cells were cultured on glass coverslips. The control cells developed a complete monolayer, 
while all claudin-7 KD cells showed spheroid colonies. KD+b1 cells formed a partial monolayer 
with a spheroid cell clump, indicating incomplete cell spreading. The phase images were 
photographed at 100 × magnification. Scale bar: 10 μm. B. A scratch was created using a pipet tip 
on each confluent control, KD, and KD+b1 cell monolayer. Both control and KD+b1 cell layers 
were attached to the plate fairly well, whereas claudin-7 KD cells were stripped off along the 










Figure III.3 Exogenous β1 integrin expression partially recovered cell migration ability of 
claudin-7 KD cells. 
A. A panel of representative light phase images of control, KD, and KD+b1 cells in wound healing 
assay plates was photographed at 200 × magnification at a specified time point. Scale bar: 10 μm. 
B. Relative cell migration rate on each cell line in wound healing assay. The relative cell migration 
distance was estimated as the ratio of the closed gap distance at a given time point over the initially 
created gap distance at the 0 time point. KD+b1 cells migrated more effectively than claudin-7 KD 










Figure III.4 Exogenous β1 integrin expression partially recovered the cell invasion ability of 
claudin-7 KD cells. 
A. A panel of representative light phase images of control, KD, and KD+b1 cells was photographed 
at 200 × magnification. Scale bar: 20 μm. B. Cell invasion assay. The numbers of nuclei stained 
by blue dye (Hema-3 Solution II) were counted and averaged from five randomly chosen areas per 
cell line from three independent experiments. Red-dye (Hema-3 Solution I) staining reflected 









Figure III.5 Both β1 integrin and claudin-7 improved the cell attachment capability of 
claudin-7 KD cells to different degrees. 
A. Cell attachment assay testing the effect of β1 integrin overexpression in KD cells. A total of 2 
× 105 cells per cell line were seeded in a 12-well plate and incubated for 4 h at 37°C in a 5% CO2 
humidified incubator. After unattached cells were washed briefly with PBS buffer, the remaining 
attached cells were trypsinized and counted for evaluation. KD+b1 cells showed significantly more 
attached cells than claudin-7 KD cells (*p < 0.01) but significantly fewer than control cells (*p < 
0.05). At least three experiments were repeated for statistical analysis. B. Cell attachment assay 
testing the effect of claudin-7 overexpression in claudin-7 KD cells. A total of 1 × 105 control, KD, 
and KD+cldn7 cells were seeded in a 24-well plate and incubated for 4 h at 37°C in a 5% CO2 
incubator. Unattached cells were washed briefly using PBS buffer, and remaining attached cells 
were trypsinized and counted for evaluation. KD+cldn7 cells increased the attached cell numbers 
significantly more than both KD cells (*p < 0.01) and control cells (*p < 0.05). At least three 
repetitive experiments were performed for statistical analysis. C. Representative Western blot 
result on protein expression levels of focal adhesion proteins in control, claudin-7 KD, KD+b1, 
and KD+cldn7 cells. KD+b1 cells increased the expression levels of β1 integrin and phospho-FAK 
but not phospho-Paxillin when compared to KD cells. KD+cldn7 cells increased the protein 
expression levels of β1 integrin, phospho-FAK, and phospho-Paxillin. KD+cldn7 cells showed 
both an exogenous claudin-7 band at 22 kDa with Myc-tag and endogenous claudin-7 expression 




CHAPTER IV. CLAUDIN-7 REGULATES GLUCOSE METABOLISM FOR CELL 
SURVIVAL OF HUMAN LUNG CANCER CELLS 
A. Summary 
Claudins are a family of TJ membrane proteins involved in human lung cancers. It has been 
documented that lung cancer patients with high claudin-7 expression survive longer than those 
with low claudin-7 expression after physical surgery. Our previous study has shown that 
suppressing claudin-7 expression in a human lung adenocarcinoma HCC827 cells significantly 
increased cell proliferation in culture and tumor growth in mice. To investigate how the tumor 
microenvironment facilitates claudin-7 regulation of cell survival, we treated the control and 
claudin-7 KD cells under hypoxia (1% O2) for 3 days in light microscopic and cell counting studies 
and for 1 day in an immunofluorescence staining study to count the cells with cleaved PARP 
indicating cell death. The results showed that claudin-7 KD reduced cell death more effectively in 
cell counting (p < 0.01) and immunofluorescence staining assays (p < 0.001). The KD cells 
displayed fairly normal-looking morphologies, whereas the control cells displayed shrunken cell 
morphologies. To examine how claudin-7 modulates glucose metabolism for cell survival, the cells 
were first pre-treated with a normal (2 g/L) glucose-containing medium in atmospheric oxygen 
conditions (normoxia) for 2 days. The cells were sub-cultured with a normal or low (0.2 g/L) 
glucose-containing medium in either hypoxia or normoxia up to an additional 24 h for the short-
term hypoxia study, or the cells were subject to low glucose and hypoxic conditions up to an 
additional 72 h for the chronic hypoxia study. In the Western blot analysis, the short-term hypoxia 
study revealed substantial inhibition (or phosphorylation) of a negative regulator of glycogen 
synthesis, GSK3β, and a dramatic decrease in a cellular energy sensor, phospho-AMP kinase, in 




chronic hypoxia study, the KD cells greatly reduced glucose-6-phosphate dehydrogenase (G6PD) 
and increased phospho-pyruvate kinase M2 isoform, suggesting a prompt decrease in DNA 
synthesis and glycolysis. We conclude that claudin-7 regulates the cell survival and glucose 
metabolism of human lung cancer cells. 
 
B. Introduction 
Lung cancer is one of the leading causes of mortality in the United States (32). Of all cases, 
85% were diagnosed as NSCLC, and the five-year survival rate is 15% (33). Lung tissue expresses 
various TJ proteins depending on their compartments, including claudin-1, -2, -3, -5, -7, -8, and -
18 (92). TJ proteins are major cellular junctional transmembrane proteins mainly located at the 
apical side of the epithelial cells, and they regulate fluid exchange, called paracellular permeability 
activity, between neighboring cells (106) and the uptake of selective ions (93, 106). Claudins are 
one of the TJ proteins; they consist of four transmembrane spanning proteins (93), and they interact 
with other TJ proteins, including Zonula Occludens, Occludins, and actin cytoskeletons, to 
establish apical cell polarity (106). It has been well established that claudins function as physical 
and physiological epithelial barriers for maintenance, cell polarity, and water and selective ion 
transport (93, 106), but their roles in disease, including cancer, remain unclear.  
Several studies have shown an interconnection between TJ proteins and cancer cell growth. 
Dhawan et al demonstrated that overexpressing claudin-2 in colon cancer cells resulted in 
increased tumor cell numbers in culture in vitro and tumor size in mice in vivo (107). The authors 
also found that providing EGF in the colon cancer cell culture increased claudin-2 expression 
levels in vitro. Claudin-7-overexpressing cervical tumor cell lines have also been found to exhibit 




protein in human bladder cancer cell lines has been shown to decrease cell proliferation and 
increase cell apoptosis in vitro (109). Although these reports suggest that claudins support cancer 
cell growth, whether claudin expression always contributes to cancer cell growth and the way in 
which claudin regulates cancer cell growth and apoptosis remain unclear. Recently, it has been 
clinically reported that the survival rate of lung cancer patients is strongly inversely associated 
with their level of claudin-7 expression within five years of physical surgery (35), suggesting that 
the loss of claudin-7 expression appears to expedite lung cancer progression. These findings 
discussed above suggest that correlation between cancer progression and claudin expression 
depends on cancer type. 
Similarly, our previous study has demonstrated that claudin-7 KD in HCC827 human lung 
cancer cells increases cell proliferation in cell culture in vitro and mouse tumor growth in nude 
mice in vivo (66). In the in vivo mouse study, mouse tumor tissues derived from claudin-7 KD cells 
substantially increased both cell apoptosis (cleaved PARP) and the inhibitor of cell apoptosis 
(survivin) when compared to those derived from control cells (66). This suggests that claudin-7 
KD cells induce an anti-apoptotic factor to prevent tumor cell death, although the KD cells do not 
fully inhibit the apoptosis caused by expedited mouse tumor growth that could also establish a 
tumor microenvironment, such as low oxygen (hypoxia) and low nutrient (including glucose) 
conditions. 
A shift in cancer metabolism to generate cellular energy occurs in order to sustain the 
massive tumor cell growth (62). In the hypoxic environment, stabilized HIF changes glucose 
metabolism to aerobic glycolysis, which permits fast cancer growth by providing cellular energy 
in an inefficient manner but at a faster rate when compared to normally growing non-cancer cells 




breakdown to pyruvate, which leads to the production of lactate and 2 ATPs at a faster rate in 
cancer cells, whereas normally growing non-cancer cells direct pyruvate to the TCA cycle for the 
oxidative phosphorylation of pyruvate in mitochondria, which produces an additional 34 ATPs 
(64).  
Changes in the cellular energy level are monitored by an energy sensor kinase called 
adenosine monophosphate kinase (AMPK) (62, 63). It is activated by phosphorylation at the 
threonine 172 site (phospho-AMPK) when adenosine monophosphate (AMP) is high or cellular 
energy is low (110). The activated AMPK promotes ATP generation through anabolic metabolism, 
such as fatty acid oxidization, and inhibits fatty acid synthesis (111, 112). AMPK also induces 
autophagy that breaks down and recycles cellular components to generate ATP (113). Interestingly, 
it has been reported that AMPK expression in lung cancer patients is correlated with their survival 
rate (114), suggesting that AMPK promotes anti-tumor activity. 
In order to avoid impaired tumorigenesis, cancer cells are capable of storing glycogens by 
HIF-1α or HIF-2α induction under hypoxia conditions for cancer cell survival in the event of 
glucose withdrawal conditions (115). In addition, the breakdown of glycogen by glycogen 
phosphorylase under limited glucose conditions has been prominently reported to protect cancer 
cells from undergoing either cancer apoptosis or premature senescence induced by ROS (116, 117). 
This suggests that glycogen stored within cancer cells is used to provide glucose for glycolysis in 
generating cellular energy and for the pentose pathway in synthesizing antioxidants, such as 
nicotinamide adenine dinucleotide phosphate (NADPH) and glutathione (GSH), which neutralize 
ROS. However, the way in which claudin is linked to cancer cell metabolism for cell survival has 
not been extensively investigated.  




and the way in which claudin-7 modifies glucose metabolism in the tumor microenvironment in 
vitro. We demonstrate that claudin-7 KD lung cancer cells have the potential to synthesize 
glycogen as an energy source upon hypoxia. Our report shows that claudin-7 KD cells further 
reduce cancer cell apoptosis by reprogramming glucose metabolism in favor of lung cancer cell 
survival when compared to control cells.  
 
C. Materials and methods 
 
C.1.Antibodies 
Rabbit polyclonal anti-Histone H3 (Cat. No. 9715), anti-phospho-Thr172-AMPKα (Cat. 
2531), anti-AMPKα (Cat. 2795), anti-phospho-Ser9-GSK3β (Cat. 9336), anti-phospho-Y105- 
pyruvate kinase isozymes M2 (PKM2) (Cat. 3827), anti-PKM2 (Cat. No. 3198), anti-G6PD (Cat. 
8866), and mouse monoclonal anti-α-tubulin (Cat. 3873) were purchased from Cell Signaling 
Technology. Rabbit polyclonal anti-claudin-7 antibody (Cat. 18875) was obtained from Immuno-
Biological Laboratories. Rabbit polyclonal anti-HIF-1α (Cat. SC-10790) and anti-Glut1 antibodies 
(Cat. PA1-16152) were purchased from Santa Cruz Biotechnology and Thermo Scientific, 
respectively. Mouse monoclonal anti-GSK3β (Cat. 610201) antibodies from BD Transduction 
Laboratories were a kind gift from Dr. Qun Lu at East Carolina University. Secondary anti-mouse 
(Cat. W4021) and anti-rabbit (Cat. W4011) antibodies conjugated with HRP were obtained from 
Promega.  
 
C.2.Cell lines and reagents 




medium (Cat. 11875-093, Gibco, Long Island, NY) supplemented with heat-inactivated 10% fetal 
bovine serum (Cat. SH3007001, HyClone) and 1% 10,000 U/ml penicillin and 10,000 μg/mL 
streptomycin (Cat. 15140-122, Gibco, Carlsbad, CA) at 37°C in a 5% CO2 humidified incubator 
in atmospheric oxygen conditions. HCC827 control and claudin-7 KD cell lines were established 
as previously described [1]. For hypoxia treatment, cells were treated at 1% O2 and harvested inside 
the Invivo2 400 hypoxia workstation (Baker Ruskinn, Sanford, ME).  
 
C.3.Treatment of cell culture to mimic tumor microenvironment in vitro 
In order to mimic the tumor microenvironment in vitro, HCC827 control and claudin-7 KD 
cells were pre-cultured in a poly-D-lysine-coated 8-well plate (Cat. 354632, BD Biocoat, Rockford, 
IL) in normal (2 g/L) glucose-containing medium and at 37°C in a 5% CO2 humidified incubator 
in atmospheric oxygen conditions (normoxia) for 2 days. They were then sub-cultured in either 
normal or low (0.2 g/L) glucose-containing medium at 37°C in a 5% CO2 humidified incubator in 
1% oxygen conditions (hypoxia) up to an additional 1 day for the short-term hypoxia study or 3 
days for the chronic hypoxia study.  
The chronic hypoxia study was conducted in hypoxia and low glucose culture conditions 
in order to mimic the tumor microenvironment in vitro, without replenishing with fresh cell culture 
media. Six sites per cell line were randomly selected at 200 × magnification using a Zeiss Axiovert 
S100 inverted light microscope (Carl Zeiss Inc.) and photographed using Axiovision 4.6 imaging 
software (Carl Zeiss Inc.). 
 
C.4.SDS-PAGE, Western blot, and cell fractionation 




dodecyl sulfate, 150 mM sodium chloride, 2 mM ethylene diamine tetraacetic acid, 10 mM sodium 
pyrophosphate, 20 mM sodium fluoride) supplemented with a complete protease inhibitor cocktail 
tablet (Cat. 11836153001, Roche Diagnostics) and phosphatase inhibitors, including 1 mM sodium 
orthovanadate and 1 mM hydrogen peroxide. Supernatants from the protein lysate were separated 
from cell debris by centrifugation at 4°C, and protein concentration was measured using a PierceTM 
BCA Protein Assay Kit (Cat. 23225, Thermo Scientific). Next, 20 μg of protein were loaded and 
separated for each well of SDS-PAGE gel, transferred to a nitrocellulose membrane (Amersham 
Protran 0.45 NC, GE Healthcare) by electrophoresis, and then blocked and immuno-blotted with 
appropriate primary antibodies followed by peroxidase-conjugated secondary antibodies. Protein 
bands were detected using ECL detection reagent (GE Healthcare) and photographed using an X-
ray film developer. Cell fractionation was performed to separate cytosolic and nuclear extracts to 
probe for HIF-1α in the Western blot according to the instructions of NE-PER Nuclear and 
Cytoplasmic Extraction Reagents (Cat. 78833, Thermo Scientific). Histone H3 and α-tubulin 
served as loading control proteins in nuclear extracts and cytosolic extracts, respectively. 
 
C.5.Cell counting assays 
HCC827 control and claudin-7 KD cells cultured for 2 days in normal glucose and 
normoxic conditions were sub-cultured under hypoxia (1% O2) in an 8-well plate up to 24 h or 72 
h. Dead and total cell numbers were counted for the 72-h hypoxia study using the trypan blue 
exclusion method in a CountessTM automated cell counter (Cat. C10227, Invitrogen). The 





C.6. Immunofluorescence staining 
The cells sub-cultured for 1 day under hypoxia were fixed in -20°C ice-cold methanol for 
5 min and briefly washed with phosphate buffered saline (PBS). They were blocked with 3% BSA, 
incubated with poly rabbit anti-cleaved PARP antibody solution (1:200) and anti-rabbit Cyt3-
tagged antibody solution (1:400) for 1 h each in series at room temperature, and then treated with 
Hoechst (1:5000) for nucleus staining for 1 min. The labeled cells were mounted with Antifade 
solution (Invitrogen). Six random spots per cell line were selected at 200 x magnification using a 
Zeiss Axiovert S100 laser scanning microscope (Carl Zeiss Inc.) and photographed using 
Axiovision 4.6 imaging software (Carl Zeiss Inc.). Proportions of cell populations with PARP 
cleavage were estimated by the ratio of cleaved PARP numbers over total nucleus numbers per 
spot. 
 
C.7. Statistical analysis  
All experiments were performed at least three times, and data were presented as means ± 
standard error of means. Student’s t-test was performed to compare samples from two cell lines 
using IBM’s SPSS program. We considered differences statistically significant when p < 0.05. 
 
D. Results 
D.1.Claudin-7 KD cells showed reduction in cell death under hypoxia conditions 
Our previous study has shown that claudin-7 KD in HCC827 lung cancer cells decreased 
pro-apoptosis protein (cleaved PARP) in vitro, whereas our in vivo mouse study results revealed 
an increase in both pro-apoptotic protein and anti-apoptotic protein (survivin) from mouse tumor 




claudin-7 KD cells are more resistant to cell death despite the presence of apoptotic expression 
(cleaved PARP). To examine whether claudin-7 altered hypoxia-induced cancer cell death, we 
subjected both claudin-7 control and KD cells to 1% oxygen (hypoxia) conditions without 
replenishing with new cell culture media for 3 days.  
Light microscopy revealed that the claudin-7 KD cells maintained normal-looking cell 
layers. However, given the same cell culture conditions, claudin-7 control cells showed shrunken 
shapes, suggesting significantly more apoptotic cells (Fig. IV.1.A). The cell counting assays based 
on trypan blue exclusion further confirmed that the proportion of the dead cell population was 
significantly increased in claudin-7 control cells (55%) when compared to KD cells (20%) (* p < 
0.01) (Fig. IV.1.B), indicating that the KD cells were more resistant to cell death than the control 
cells. 
In order to examine whether the resistance of claudin-7 KD cells against cell death was 
attributed to reduced apoptotic events, we evaluated the proportion of the cell population that 
underwent cell apoptotic events based on the apoptotic marker protein cleaved PARP after short-
term hypoxia treatment for 1 day. The immunofluorescence staining images demonstrated that the 
proportion of the claudin-7 KD cell population expressing cleaved PARP was also significantly 
decreased when compared to that of the control cell population (*p < 0.001) (Figs. IV.2.A and 
IV.2.B). All the results suggest that claudin-7 KD cells are able to inhibit cell apoptosis in hypoxia 
(1% O2) and that claudin-7 KD cells are resistant to hypoxia-induced cell death. 
 
D.2.Claudin-7 KD cells maintain phosphorylation of GSK3β in hypoxia and low glucose culture 
conditions 




protected from apoptotic events when compared to control cells under chronic hypoxia for up to 3 
days. This result suggests that claudin-7 KD cells overcome apoptosis in the tumor 
microenvironment by switching their cancer metabolism in support of cancer cell survival.  
To investigate whether different tumor microenvironments changed the regulation of the 
claudin-7 phenotype in glucose metabolism and cellular energy in vitro, both HCC827 claudin-7 
KD and control cells were initially cultured in normoxia (atmospheric 21% O2) and normal 
glucose-containing culture conditions for 2 days as time point 0. The pre-cultured cell lines were 
sub-cultured in four different culture conditions, including either normoxia or hypoxia (1% O2) 
and normal (2g/L) or low (0.2g/L) glucose-containing media conditions, for up to an additional 24 
h. The short-term hypoxia experiment was conducted to first examine whether claudin-7 regulates 
HIF, which controls the expression of several key enzymes, by regulating glycolysis for up to 24 
h.  
In the Western blot analysis, the HIF-1α level declined rapidly in claudin-7 KD cells 
regardless of oxygen and glucose levels by 24 h, whereas claudin-7 control cells maintained 
relatively high levels of HIF-1α in hypoxia and normal glucose culture conditions (Figs. IV.3.A 
and IV.3.B). On the other hand, glucose transport 1 protein (Glut-1) on both claudin-7 control and 
KD cells were consistently expressed in both normal and low glucose cultures in normoxia and 
hypoxia conditions regardless of claudin-7 phenotypes (Figs. IV.3.A and IV.3.B), indicating that 
claudin-7 does not extensively modulate Glut-1 protein levels to regulate glucose uptake in 
hypoxia treatment for 24 h, although levels of HIF-1α changed depending on oxygen and glucose 
levels. 
Next, we examined whether the claudin-7 phenotype modulates GSK3β, a negative 




of inhibitory phosphorylation of GSK3β at the serine 9 site (phospho-GSK3β) in claudin-7 KD 
cells was substantially higher than that of control cells for up to 24 h (Left panel, Fig. IV.3.A). A 
similar observation was also made in hypoxia and low glucose culture conditions for 24 h (Right 
panel, Fig. IV.3.A). Interestingly, HIF-1α, which is known to support glycogen synthesis in 
hypoxic conditions (118), almost disappeared in the claudin-7 KD cells in hypoxia conditions by 
24 h regardless of glucose concentration (Fig. IV.3.A). This result suggests that claudin-7 KD cells 
chiefly inhibit the activity of GSK3β so as to keep GS in active status, while HIF-1α is not available 
to sustain glycogen synthesis in hypoxia and low glucose conditions 
In normoxia and normal glucose culture conditions, inhibitory phospho-GSK3β levels 
were not noticeably different between claudin-7 control and KD cells at all time points (Left panel, 
Fig. IV.3.B). Similarly, no significant difference was found in levels of phospho-GSK3β between 
claudin-7 control and KD cells in normoxia and low glucose culture conditions. However, 
phospho-GSK3β levels of both claudin-7 control and the KD cells were slightly and equally 
increased at the 8-h time point when compared to those levels of both cells at the 0-and 24-h time 
points (Fig. IV.3.B). This result suggests that both claudin-7 control and KD cells activate GS 8 h 
after new low glucose culture media is provided, but both cells become adapted and decrease GS 
levels back to normal levels by 24 h in normoxia and normal glucose conditions. As expected, 
HIF-1α expression was not remarkably detectable at either the 8- or 24-h time points in both 
claudin-7 control and KD cells due to the presence of atmospheric oxygen, suggesting that 





D.3.Claudin-7 KD cells downregulate AMPK activation under hypoxia and low glucose culture 
conditions 
The results of our current study using four cell culture conditions has shown that GSK3β 
levels of claudin-7 control and KD cells change differently in hypoxia conditions, suggesting that 
claudin-7 modulates glucose metabolism in hypoxia conditions. Thus, we further examined 
whether claudin-7 altered AMP kinase (AMPK), which senses cellular energy levels (62, 63, 110).  
In hypoxia and normal glucose culture conditions (Left panel, Fig. IV.3.A), a Western blot 
analysis first revealed that claudin-7 control cells slightly increased levels of both active phospho-
AMPK and total AMPK by 8 h and maintained their levels for up to 24 h. Claudin-7 control cells 
also showed substantially lower levels of both active and total AMPK than claudin-7 KD cells at 
the 8- and 24-h time points, respectively. On the other hand, claudin-7 KD cells significantly 
increased levels of both active phospho-AMPK and total AMPK by 8 h. While the total AMPK 
level later remained the same, the active phospho-AMPK level quickly declined by 24 h under 
hypoxia and normal glucose culture conditions. 
On the other hand, in hypoxia and low glucose culture conditions (Right panel, Fig. IV.3.A), 
the total AMPK form of claudin-7 control cells remained at constantly lower levels than that of 
claudin-7 KD cells for up to 24 h. Similarly, claudin-7 control cells kept the highly elevated level 
of the active phospho-AMPK form for up to 24 h, but the level of the active AMPK form rapidly 
increased by 8 h and quickly dropped by 24 h in claudin-7 KD cells. A similar fluctuating pattern 
of changes in total AMPK levels was also found in the KD cells by 8 and 24 h. 
All the experimental results from the hypoxia conditions mentioned above recapitulate the 
hypothesis that the claudin-7 KD phenotype decreases AMPK activation differently depending on 




phospho-AMPK while maintaining the total AMPK level. However, when glucose levels are low, 
claudin-7 KD cells decrease levels of both active phospho-AMPK and total AMPK. This indicates 
that a decrease in the level of total AMPK is attributed to the decreased level of active AMPK. 
AMPK is a cellular energy sensor kinase that shifts glucose metabolism in a way that generates 
cellular energy, increases catabolic processes, and decreases anabolic processes when the AMP 
level is high (119). In this sense, the results of our hypoxia treatment experiments suggest that 
claudin-7 KD cells decrease active AMPK levels to promote anabolic processes in hypoxia 
treatment for up to 24 h. 
Next, we proceeded to execute our cell culture experiments in normoxia and normal 
glucose culture conditions (Left panel, Fig. IV.3.B). Both claudin-7 control and KD cells slightly 
and comparably increased the levels of both active and total AMPK forms by 8 h and decreased 
the levels of both active and total AMPK forms by 24 h. This indicates that claudin-7 control and 
KD cells equally increase both active and total AMPK levels in order to facilitate the uptake of 
freshly provided glucose for 8 h, and both claudin-7 control and KD cells later decrease their levels 
of both active and total AMPK by 24 h in normoxia (21% O2) and normal (2 g/L) glucose culture 
conditions.  
A similar shifting pattern of changes in total AMPK levels was also seen when both 
claudin-7 control and KD cells were cultured in normoxia and low glucose culture conditions for 
up to 24 h (Right panel, Fig. IV.3.B). However, the elevated active phospho-AMPK levels of both 
claudin-7 control and KD cells at the 8-h time point were kept at comparably high levels for up to 
24 h in normoxia and low glucose culture conditions. This suggests that low glucose conditions 
keep activating AMPK in both claudin-7 control and KD cells for up to 24 h. 




that both claudin-7 control and KD cells dramatically and equally decreased the levels of active 
phospho-AMPK by 24 h in normoxia and normal glucose culture conditions. However, both 
control and KD cells comparably increased active AMPK levels by 8 h and maintained the levels 
for up to 24 h in normoxia and low glucose culture conditions. These observations clearly indicate 
that glucose level controls active phospho-AMPK levels in claudin-7 control and KD human lung 
cancer cells in normoxia conditions. Similarly, several previous in vitro and in vivo studies have 
documented that high glucose treatment inhibits active phospho-AMPK levels (120). Therefore, 
the results from our current normoxia treatment experiment suggest that normoxia conditions do 
not differentially regulate levels of active phospho-AMPK between claudin-7 control and KD cells 
at all time points. 
In summary, we found that HCC827 claudin-7 KD cells greatly decreased phospho-AMPK 
levels to a further lower level when compared to that of claudin-7 control cells after 24 h hypoxia 
and low glucose culture treatment in vitro (Right panel, Fig. IV.3.A). 
 
D.4.Claudin-7 KD cells showed some reduction in glycolytic and pentose phosphate pathway in 
chronic hypoxia conditions 
All the data illustrated above point out that claudin-7 KD cells decreased cancer cell 
apoptosis and inactivated AMPK activity, and inhibited (or phosphorylated) GSK3β, which 
possibly suppressed the activity of GS in hypoxia and low glucose conditions in vitro. 
Interestingly, it has been previously documented that the β subunit of AMPK binds to 
glycogen, and it has been suggested that AMPK may interact with enzymes regulating glycogen 
synthesis, such as GS, GSK3β, and glycogen phosphorylase (121). AMPK has also been reported 




inhibit GS. Interestingly, our current experimental results have shown that claudin-7 KD cells not 
only intensely decreased active phospho-AMPK but also greatly inhibited (phosphorylated) 
GSK3β in hypoxia and low glucose conditions for up to 24 h (Right panel, Fig. IV.3.A). This 
suggests that the suppression of both GSK3β and AMPK in claudin-7 KD cells results in 
potentially activating GS in hypoxia and low glucose conditions for up to 24 h. In addition, we 
have demonstrated that claudin-7 KD cells showed a significant reduction in cell apoptosis 
(cleaved PARP) when compared to control cells after 24 h of hypoxia treatment. These 
experimental results suggest that claudin-7 KD cells protect against cell apoptosis more efficiently 
than claudin-7 control cells by potentially increasing the activity of GS through modulating GSK3β 
and AMPK. 
Based on the possible changes in glucose metabolism, we next examined whether claudin-
7 KD cells also manipulated other key genes regulating the glucose metabolic pathways, such as 
the glycolysis and pentose phosphate pathways, for cancer cell survival in chronic hypoxia and 
low glucose culture conditions for up to 3 days. 
Western blot results (Fig. IV.4.A) revealed that phosphorylation of pyruvate kinase isoform 
M2 at the tyrosine 105 site (phospho-PKM2) was slightly increased in claudin-7 KD cells after 3 
days of hypoxia and low glucose culture treatment, indicating that KD cells lead to an earlier 
reduction in the conversion of phosphoenolpyruvate (PEP) to pyruvate in aerobic glycolysis. In 
addition, claudin-7 KD cells further decreased the expression level of G6PD earlier than the 
claudin-7 control cells from 2 days of hypoxia and low glucose culture treatment. This result also 
suggests that claudin-7 KD cells decrease the pentose phosphate pathway for nucleotide synthesis 
earlier than the control cells in chronic hypoxia and low glucose conditions.  




survival by inhibiting cell apoptosis in the tumor microenvironment in vitro. They do so by 
coordinately regulating the overall glucose metabolic pathways by potentially activating GS, 
decreasing the conversion of PEP to pyruvate, and inhibiting nucleotide synthesis. 
 
E. Discussion 
Since the discovery of aerobic glycolysis or Warburg’s effect, which is still commonly 
accepted as facilitated glycolysis to produce lactate for cancer cell growth and metabolism (62), 
several broad attempts to identify other types of altered cancer metabolism have been reported. In 
the meantime, the overexpression of TJs, including claudins, in several different cancer cell lines 
has been shown to promote cancer progression, which decreases cancer cell apoptosis and 
increases cancer cell growth and metastasis in vitro or in vivo (29, 107, 122). 
 
Interestingly, several experiments using claudin overexpression do not always seem to 
support cancer cell proliferation. Cunniffe et al reported that claudin-1 and -7 overexpression in 
ovarian cancer cells did not increase cell proliferation (108). In contrast, our previous studies have 
demonstrated that claudin-7 overexpression decreases lung cancer cell proliferation in vitro (66). 
These results suggest that the interconnection between claudin expression and cancer cell growth 
is specific to certain cancer cell types. However, it is unclear whether TJs modulate cancer 
metabolism. Thus, this current study has focused on how the TJ protein claudin-7 regulates glucose 
metabolism in human lung cancer cell lines in order to promote cancer cell survival in the tumor 
microenvironment in vitro.  
Our previous in vivo study has shown that claudin-7 KD in lung cancer cell lines induces 




apoptosis (66). Although the apoptotic event was thought to suppress mouse tumor growth, the 
mouse tumor inoculated with claudin-7 KD cells still grew into a large mouse tumor when 
compared to that inoculated with claudin-7 control cells (66), suggesting that anti-apoptotic 
expression (survivin) may inhibit apoptotic cascades by binding terminal effector cell death 
caspase-3 or -7 cleavage (123). Conversely, our previous study showed that cleaved PARP was 
almost abolished while survivin was still highly expressed in claudin-7 KD cells in cell culture in 
vitro. The disparity in the induced level of cleaved PARP between in vivo and in vitro studies could 
be explained by the fact that cell culture conditions offer the free exchange of oxygen and nutrients 
to cells, which inhibits cell apoptosis (66). Overall, it is likely that tumor microenvironments, such 
as oxygen and glucose-deprived (OGD) conditions, promote better survival of claudin-7 KD cells 
by suppressing the apoptotic process, which could also allow for the acceleration of larger mouse 
tumor growth, as shown in our previous in vivo mouse study (66). Therefore, this current study 
has further investigated the way in which claudin-7 KD cells decrease cancer cell apoptosis in 
OGD conditions that mimic tumor microenvironments in vivo. 
The next main question of this current study is whether claudin-7 KD lung cancer cells 
modulate glucose metabolism to evade cell apoptosis in vitro. We observed that claudin-7 control 
cells significantly increase not only apoptosis (Figs. IV.2.A and IV.2.B) but also the potential for 
autophagy, shown as a shrunken cell shape (Fig. IV.1.A). The claudin-7 control cells seem to break 
down their cellular components often in generating cellular energy for cell survival, possibly due 
to their low cellular energy levels. In contrast, claudin-7 KD cells maintain normal-looking 
epithelial cells in the same hypoxia condition for 3 days, suggesting a possible shift in glucose 





The fate of cell survival is determined in the context of the cellular environment. For 
example, hypoxia conditions stabilize HIF, which increases glucose uptake and promotes aerobic 
glycolysis for lactate production, while HIF activates pyruvate dehydrogenase kinase 1 (PDK1) to 
inhibit pyruvate dehydrogenase (PDH) that converts pyruvate to acetyl-CoA for oxidative 
phosphorylation in the mitochondria (124). On the other hand, low glucose conditions increase 
active phospho-AMPK, which then promotes autophagy by recycling cellular components to 
produce the cellular energy required for cell survival (125, 126). However, severe hypoxia and low 
glucose conditions in combination causes high cellular stress that activates AMPK and induces 
autophagy, leading to cell death (127).  
Interestingly, the combinatory effect of both low oxygen and low glucose conditions also 
appears to induce ROS production. It has been reported that lens epithelial cells create ROS via 
protein kinase RNA-like endoplasmic reticulum kinase (PERK) signals in OGD conditions (128). 
Similarly, OGD conditions are not beneficial for the survival of certain cancer cells. For 
example, it has been shown that in hypoxia conditions, C2C12 myoblast cancer cells in low 
glucose conditions substantially reduce lactate production when compared to those cells in high 
glucose conditions (129). This suggests that aerobic glycolysis in hypoxia conditions is 
compromised due to limited glucose sources. In low glucose culture conditions, the β-oxidation of 
fatty acids, which produces acetyl-CoA, could be an alternate pathway to produce ATP. Consuming 
the acetyl-CoA to produce ATP requires TCA cycles through mitochondrial oxygen respiration. 
Thus, hypoxia and low glucose culture conditions eventually hinder the pathway of β-oxidation of 
fatty acids.  
Our data suggest that under OGD conditions, claudin-7 KD cells rapidly decrease active 




GS, but control cells increase active phospho-AMPK and decrease inhibitory phospho-GSK3β, 
which possibly suppresses the activity of GS. Thus, it appears that claudin-7 KD cells could 
synthesize more glycogen than control cells in hypoxia conditions, although we have not directly 
measured the content of glycogen within both claudin-7 control and KD cells. Therefore, we need 
to conduct a follow-up investigation to evaluate the amount of stored glycogen in both claudin-7 
control and KD human lung cancer cells.  
Although some glucose is necessary to maintain HIF-1α in hypoxia conditions (130), 
claudin-7 KD cells significantly reduced HIF-1α expression unlike the control cells after 24 h of 
hypoxia and normal glucose culture treatment (Left panel, Fig. IV.3.A). It is possible that in the 
HCC827 claudin-7 KD cells, aerobic glycolysis in hypoxia conditions may not be in high demand 
to maintain sufficient cellular energy levels for cell survival by increasing inhibitory phospho-
GSK3β. Similarly, we found that the active phospho-AMPK level was dramatically reduced in 
claudin-7 KD cells when compared to control cells at the 24-h time point in OGD conditions (Right 
panel, Fig. IV.3.A). These results suggest that claudin-7 KD cells inactivate (or dephosphorylate) 
AMPK to evade the possible cell apoptosis resulting from the high cellular stress caused by OGD 
conditions. The increase in phospho-GSK3β and decrease in phospho-AMPK may constitute a 
metabolic phenotype of claudin-7 KD cells. Interestingly, it has been well established in a clinical 
report that reduced AMPK levels are strongly associated with lower survival rates of lung cancer 
patients (114). Another clinical group has also documented that low claudin-7 expression results 
in reduced survival rates of lung cancer patients (35). Considering that claudin-7 KD cells exhibit 
substantially decreased activity of AMPK by reducing either active phospho-AMPK or total 
AMPK levels in claudin-7 KD cells depending on glucose levels, it seems that claudin-7 and 




AMPK or vice versa in lung cancer progression remains unclear. 
Next, we also investigated how claudin-7 KD cells modulated glucose metabolism in order 
to avoid cell apoptosis-induced cell death under chronic hypoxia conditions for up to 3 days, as 
claudin-7 KD cells maintained normal-looking cell layers whereas control cells shrunk (Fig. 
IV.1.A). It has been well established that cancer cells regulate PKM2 to reroute glucose flux from 
the glycolytic pathway to the pentose phosphate pathway in order to build up nucleotides and 
protect cancer cells against ROS by generating the antioxidants NADPH and GSH for cancer cell 
survival (131). As expected, our experimental results revealed that phospho-PKM2 levels were 
slightly increased in claudin-7 KD cells when compared to control cells after 3 days of OGD 
conditions (Fig. IV.4.A). However,  G6PD was substantially reduced in the KD cells from day 2 
(Fig. IV.4.A), suggesting that claudin-7 KD cells slow down glucose flux toward the pentose 
pathway earlier than control cells under OGD conditions. Consequently, claudin-7 KD cells are 
likely to reduce levels of antioxidants, including NADPH and GSH, due to the possibly decreased 
pentose phosphate pathway. This observation has raised the question of how claudin-7 KD cells 
can protect against cell death by increased ROS in OGD conditions without obtaining sufficient 
levels of antioxidants through the pentose phosphate pathway.  
It is possible that claudin-7 KD cells immediately decrease nucleotide synthesis in order to 
avoid severe DNA damage by ROS in OGD conditions that could result in apoptosis. In addition, 
claudin-7 KD cells could also produce more GSH and NADPH through an altered glucose 
metabolic pathway to protect themselves against DNA damage. For example, it has been 
established that a glucose metabolite, 3-phosphoglycerate (3PG), can be used to synthesize serine 
and glycine, both of which are conjugated with glutamate to synthesize GSH (132).  




modulating HIF. We found that claudin-7 KD cells rapidly reduced HIF-1α levels by 24 h in 
hypoxia treatment when compared to claudin-7 control cells (Left panel, Fig. IV.3.A). HIF-1α 
activates PDK, which inhibits PDH (133). PDH is responsible for converting pyruvate into acetyl-
CoA for its entry to the TCA cycle (133). In this sense, claudin-7 KD cells seem to gain access to 
TCA cycles in order to produce more ATP due to their abolished HIF-1α expression 24 h after 
hypoxia treatment. It has been documented that several advanced-staged cancer cells access the 
TCA cycle by activating PDH in addition to aerobic glycolysis (134). 
For NSCLC cells, pyruvate carboxylase (PC) has also been documented to convert from 
pyruvate to oxaloacetate in order to participate in the TCA cycle, which also generates GSH to 
protect lung cancer cells against ROS and support their cell proliferation (135). In addition, cancer 
cells under nutrient-deprived conditions have been demonstrated to induce endoplasmic reticulum 
(ER) stress, which activates mitochondrial phosphoenolpyruvate carboxykinase (PEPCK-M) that 
converts from oxaloacetate in mitochondria to PEP for gluconeogenesis (136). This metabolic shift 
also provides TCA cycles with the majority of oxaloacetate and pyruvate that originates from 
lactate (136). These findings suggest that lung cancer cells can also use lactate to fuel the TCA 
cycle in generating cellular energy ATP and antioxidant GSH in nutrient-deprived conditions. 
Moreover, the accumulation of fumarate and succinate in the TCA cycle due to mutations in 
fumarate hydratase (FH) and succinate dehydrogenase (SDH) in cancer cells has been reported to 
suppress the degrading activity of prolyl hydroxylase (PH) for HIF-1α (137). We are not aware of 
whether claudin-7 directly regulates the genes encoding for FH and SDH enzymes. However, 
claudin-7 KD cells almost abolished HIF-1α expression, unlike control cells, after 24 h of hypoxia 
(Fig. IV.3.A). Thus, the KD cells are likely to preserve the degradative activity of PH for HIF-1α 




running the TCA cycle, which could decrease the amount of available fumarate and succinate. 
Likewise, claudin-7 KD cells could also modulate the TCA cycle in such a way that more 
antioxidant GSH is generated and the ROS generation caused by ER stress in OGD conditions 
through TCA cycles is minimized, as previously discussed (128).  
We conclude that claudin-7 regulates the genes responsible for glucose metabolism for the 
survival of lung cancer cells under tumor microenvironments. 
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Figure IV.1 Claudin-7 KD inhibited hypoxia-induced cell death. 
Both claudin-7 control and KD cells were cultured in poly D-lysine-coated 8-well plates under 
normoxia and normal (2 g/L) glucose-containing media conditions for 2 days. Then, both cells 
were sub-cultured in hypoxia for 3 days. A. Three days after hypoxia treatment, six random spots 
of cell shapes per cell line were photographed at 100 × magnification using a Zeiss Axiovert S100 
inverted light microscope (Carl Zeiss Inc.) and photographed using Axiovision 4.6 imaging 
software (Carl Zeiss Inc.). Scale bar: 10 μm. B. Claudin-7 KD cells showed a significant reduction 
in the proportion of the cell death population when compared to control cells (*p < 0.01). At least 










Figure IV.2 Claudin-7 KD cells reduced cell apoptosis. 
Both claudin-7 control and KD cells were cultured in poly-D-lysine-coated 8-well plates under 
normoxia and normal (2 g/L) glucose-containing media culture for 2 days. Then, both cells were 
sub-cultured in hypoxia for 1 day and fluorescently labeled for PARP cleavage indicating cell 
apoptosis. A. Representative immunofluorescent images. Cleaved PARP and nuclei were 
respectively double-labeled as red and blue spots. The proportion of the apoptotic cell death 
population was estimated by the ratio of numbers of cleaved PARP over numbers of nuclei. Six 
random spots per cell line were selected at 200 x magnification using a Zeiss Axiovert S100 laser 
scanning microscope (Carl Zeiss Inc.) and photographed using Axiovision 4.6 imaging software 
(Carl Zeiss Inc.). Scale bar: 50 μm. B. Claudin-7 KD cells showed a dramatically decreased 
proportion of the apoptotic cell population when compared to control cells (*p < 0.001) At least 










Figure IV.3 Claudin-7 KD cells modulated genes of glucose metabolism in hypoxia and low 
glucose culture conditions for cancer cell survival. 
A Western blot analysis was performed in four different cell culture environments, including low 
glucose and low oxygen conditions mimicking the tumor microenvironment in vitro. Cell 
fractionation was performed to probe for HIF-1α, and Histone H3 served as a loading control 
protein in nuclear lysate. α-Tubulin served as a loading control protein in whole lysate, and it was 
not detected in nuclear lysate. Glut-1 expression levels were shown to be equal over all four cell 
culture conditions. A. Representative Western blot images on protein expression levels of phospho-
Ser9-GSK3β and phospho-Thr172-AMPK in hypoxia (1%O2) and either normal (2 g/L) or low 
(0.2 g/L) glucose culture conditions. HIF-1α was rapidly decreased in claudin-7 KD cells when 
compared to control cells at 24 h, particularly in hypoxia and low glucose culture conditions. 
Claudin-7 KD cells maintained higher levels of phospho-GSK3β than control cells up to 24 h after 
hypoxia treatment. The KD cells also dramatically decreased phospho-AMPK levels when 
compared to control cells at the 24-h time point in hypoxia and low glucose culture conditions. B. 
Representative Western blot images on protein expression levels of phospho-GSK3β and phospho-
AMPK in normoxia and either normal (2 g/L) or low (0.2 g/L) culture conditions. Neither phospho-
AMPK nor phospho-GSK3β differed dramatically from claudin-7 control and KD cells in either 









Figure IV.4 Claudin-7 KD cells suppress genes of glycolysis and nucleotide synthesis in 
chronic hypoxia and low glucose culture. 
A Western blot analysis was performed in both claudin-7 control and KD cells cultured in hypoxia 
(1%O2) and low (0.2 g/L) glucose conditions for up to an additional 3 days. α-Tubulin served as a 
loading control protein. Glut-1 expression levels were shown to be equal for up to 3 days. A. 
Representative Western blot images on protein expression levels of G6PD and phospho-PKM2 in 
hypoxia and low glucose culture conditions for up to an additional 3 days. G6PD levels were 
further decreased in claudin-7 KD cells when compared to control cells from day 2. In contrast, 
phospho-PKM2 was maintained at a slightly higher level in KD cells when compared to control 
cells on day 3. B. Schematic diagram of relationship between lung cancer cell survival and 
glycogen synthesis kinase 3β. In hypoxia and low glucose culture conditions, claudin-7 KD cells 
maintain higher levels of the inhibitory phosphorylated form of GSK3β than control cells in 




CHAPTER V. CONCLUSIONS AND DISCUSSION 
 
Cells generate and receive various cell signals from one another to regulate their cellular 
functions of proliferation, differentiation, homeostasis, and migration (1). Understanding cellular 
communication is essential to dissect the processes of diseases, including cancers. Recently, it has 
been brought to our attention that the TJ protein claudin modulates carcinogenesis in several 
human cancers (26-31). However, the roles of TJ proteins in human lung cancer cells have not 
been extensively investigated.  
Human lung cancer is the second leading cause of cancer patients’ death in the United 
States (32). About 85% of human lung cancers are categorized as NSCLC types, while the 
remaining 15% are categorized as small-cell lung cancer (SCLC) types (33). Numerous molecular 
epidemiological research studies have successfully identified potential causes of lung cancer 
incidences from alteration in genes responsible for tumor suppression as well as cell proliferation 
and survival, such as p53 and K-ras in addition to epigenetic modification such as DNA 
methylation (34), whereas the underlying cellular mechanisms of lung carcinogenesis remain 
unknown. Recently, a clinical research team found that low claudin-7 expression in lung cancer 
patients was closely associated with their low survival rate after physical surgery (35). Like other 
TJ proteins, claudin proteins are usually located at the apical side of human epithelial cells (8). 
However, claudin-7 has been found at the basal side of several human organs and tissues, including 
uterine, kidney, mammary gland, and intestines (36-39). Claudin-7 has also been found to be 
involved in the physiological activity of pregnant female rats by altering the claudin-7 protein 
expression level at the basal side of the rat uterus (36, 41). Therefore, claudin-7 in epithelial tissues 




strived to dissect the unknown function of claudin-7 in lung carcinogenesis, including cancer 
initiation, promotion, and progression, in this dissertation. 
Chapter II was published as my co-first-authored manuscript documenting that claudin-7 
regulates lung cancer cell proliferation, cell survival, and cell-matrix attachment through β1 
integrin using human lung cancer cells (66). These findings offer numerous clues on the roles of 
the TJ claudin-7 protein in potentially regulating lung carcinogenesis. First, the hyper-cell 
proliferation found in the claudin-7 KD of human lung cancer cells appears to fit the characteristics 
of cancer promotion (56), whereas cell detachment from the ECM and reduction in β1 integrin are 
well suited to cancer progression and metastasis (60). Based on these results of how claudin-7 
regulates cell-matrix adhesion in Chapter II, we examined how claudin-7 and β1 integrin co-
regulate cell-matrix adhesion and the cell migration, invasion, and attachment of human lung 
cancer cells in Chapter III, which elucidates how claudin-7 contributes to lung cancer progression 
and metastasis. Next, as claudin-7 KD in human lung cancer cells promoted cell survival, as 
described in Chapter II, we also extended our investigation of whether claudin-7 regulates cell 
metabolism for cancer cell survival under tumor microenvironments in Chapter IV. This also 
provides evidence of how claudin-7 augments cancer metastatic potential, including resistance to 
cancer cell apoptosis, in lung cancer promotion and progression. 
The first distinguishable feature of claudin-7 KD in human lung cancer cells is concomitant 
dysregulation of β1 integrin expression (66). β1 integrin is a ubiquitous major anchoring junction 
(66) that helps cells receive extracellular signals from extracellular environments such as the ECM 
through cell-matrix adhesion and respond to those external environmental stimuli (138). β1 
integrin also regulates cell migration and invasion through cell-matrix adhesion (45, 46, 48). 




enhance the cell-matrix adhesion of claudin-7 KD cells and evaluated whether the overexpression 
of β1 integrin strengthens cell migration and invasion and the attachment of KD cells. Our results 
demonstrated that the overexpression of β1 integrin highly improved cell migration and invasion 
and the attachment of claudin-7 KD cells. However, β1 integrin overexpression in claudin-7 KD 
cells could not fully recover focal adhesion proteins, unlike the re-expression of claudin-7 in 
claudin-7 KD cells. This suggests that claudin-7 has a far greater influence than β1 integrin on 
controlling cell-matrix adhesion, cell migration and invasion, and the attachment of human lung 
cancer cells through the cell-matrix interface.  
For cancer metastasis, cancer cells need to detach from the ECM before entering the blood 
circulation (52). Thus, claudin-7 KD in human lung cancer cells is thought to augment the 
metastatic potential, although it suppresses β1 integrin, focal adhesion, and cell-matrix attachment. 
Claudin-7 KD human lung cancer cells also show additional evidence that support an increased 
metastatic potential. In normal cells, the loss of β1 integrins has been documented as a negative 
consequence, such as reduced cell proliferation in the mammary glands (99, 100) and death of β1 
integrin-knockout mice before birth (99). These findings indicate that β1 integrin is necessary for 
the cell proliferation and survival of normal epithelial cells. In contrast, claudin-7 KD human lung 
cancer cells have been shown to retain hyper-proliferation and reduced apoptosis despite 
significant reductions in β1 integrin (66). This suggests that the increased metastatic potential of 
claudin-7 KD cells inhibits anoikis, a type of cell apoptosis induced by cell detachment from the 
ECM (53).  
The ability of cancer cells to survive without cell-matrix-adhesion seems important for 
cancer metastasis through blood circulation. Our previous in vivo mouse tumor growth study first 




showed expedited tumor growth in terms of both size and weight when compared to those injected 
with claudin-7 control cells (66). This suggests that a significant reduction in β1 integrin in claudin-
7 KD human lung cancer cells leads to anchorage-independent growth regardless of the context of 
the extracellular environment in vivo. In addition, the enlarged mouse tumor formation induced by 
claudin-7 KD lung cancer cells could be due to angiogenesis. We previously found that claudin-7 
KD in both HCC827 lung cancer cells and T84 breast cancer cells similarly increased the gene 
expression of metalloproteinases (MMPs) such as MMP3 in vitro (40). MMP3 has been well 
known to activate other MMPs, including collagenase, gelatinase, and matrilysin, all of which can 
promote ECM remodeling (139). MMP3 gene expression levels have also been strongly associated 
with the angiogenesis factor vascular endothelial growth factor (VEGF) at the plasmid level (140). 
These findings suggest that HCC827 claudin-7 KD human lung cancer cells are able to promote 
cancer metastasis and facilitate angiogenesis. 
In addition, our current experiment in culturing HCC827 claudin-7 KD human lung cancer 
cells in hypoxia and low glucose culture conditions has illustrated that claudin-7 KD cells were 
more resistant to cell apoptosis and increased inhibitory phospho-GSK3β. As we previously 
discussed in Chapter IV, one plausible explanation is that claudin-7 KD cells survive better than 
the control cells in such a way that glycogen synthesis may be indirectly promoted through 
potentially active GS, which is stimulated by preserving elevated levels of inhibitory phospho-
GSK3β under tumor microenvironments. More importantly, GSK3β plays a crucial role in 
upholding cancer metastasis. It has recently been reported that human gastrointestinal (GI) cancer 
cells increased inhibitory phospho-GSK3β when Fas ligand (FasL) induced an epithelial 
mesenchymal transition (EMT), which subsequently upregulated the transcriptional activity of β-




expression of inhibitory phospho-GSK3β in GI patients was closely associated with their low 
survival rate (141), indicating that phospho-GSK3β is connected to the malignancy of human GI 
cancer. Furthermore, Snail has been said to inhibit cell cycles during embryogenesis, and high 
Snail-expressing Madin–Darby canine kidney (MDCK) cell lines have been shown to develop 
resistance to cell death under serum-deprived culture conditions (142). Interestingly, high Snail-
expressing MDCK cells have also increased cell death in low glucose culture media and reduced 
several genes of enzymes responsible for TCA cycles, whereas high Snail-expressing cells have 
survived better than control vector-expressing cells in hypoxia and sufficient glucose culture 
conditions (143). However, the authors did not report on whether low glucose media also induced 
the cell death of the high Snail-expressing cells in hypoxia conditions.  
All these findings indicate that cancer cells under EMT increase phospho-GSK3β levels, 
induce high Snail expression, and become resistant to cell death in hypoxia when glucose is 
provided at an appropriate level, whereas those cells are highly dependent on glucose levels for 
cell survival in normoxia. These features, similar to those of cancer cells undergoing EMT, also 
appear in our claudin-7 KD human lung cancer cells from the following observations. Our current 
study has first revealed that the claudin-7 KD cells were more resistant to cell death in hypoxia 
and normal glucose culture conditions for 3 days. Next, claudin-7 KD cells showed highly elevated 
levels of phospho-GSK3β expression when compared to claudin-7 control cells in hypoxia and 
normal or low glucose conditions for up to 24 h. Lastly, we also found that claudin-7 KD cells 
started to reduce the expression level of G6PD earlier than the control cells from 2 days after 
hypoxia and low glucose treatment. This last observation seen in OGD conditions particularly 
appears to reflect the possibility of the EMT of the claudin-7 KD cells inhibiting nucleotide 




the characteristics of cancer cells undergoing EMT discussed above. Future investigation will 
clarify possible EMT induction in claudin-7 KD lung cancer cells in OGD conditions. 
In the meantime, we unexpectedly observed the rapid reduction of HIF-1α expression in 
the claudin-7 KD cells when compared to the control cells in hypoxia and normal glucose culture 
conditions up to 24 h. HIF-1α activates PDK, which inhibits PDH (133), and PDH is responsible 
for converting pyruvate into acetyl-CoA for its entry to the TCA cycle (133). Thus, it is possible 
that rapidly disappearing HIF-1α allows the claudin-7 KD to gain access to the TCA cycle earlier 
than the claudin-7 control cells 24 h after hypoxia and normal glucose culture treatment. In this 
sense, however, oxidative phosphorylation through the TCA cycle is also likely to generate more 
ROS, which could result in more significant cell death in the claudin-7 KD lung cancer cells. This 
could not explain why claudin-7 KD lung cancer cells significantly reduced cell death in hypoxia 
and normal glucose conditions for 3 days in our current study. One possible explanation is that 
claudin-7 KD cells might modify the TCA cycle in such a way that cellular energy and antioxidants 
including NADPH and GSH are generated while oxygen respiration is minimized, as described in 
Chapter IV.  
Alternatively, it has recently been documented that lymphoma cells with high Myc 
expression drive glutaminolysis to consume glutamate in generating cellular energy and GSH in 
the TCA cycle in a glucose-independent manner, and the inhibition of glutaminolysis has increased 
ROS (144). In addition, in the same study, lymphoma cells in hypoxia and glucose-withdrawal 
conditions did not proliferate but continuously consumed glutamate to maintain cancer cell 
viability. Interestingly, c-Myc is highly expressed in HCC827 human lung cancer cells (145). In a 
similar way, claudin-7 KD is also likely to drive HCC827 cells to glutaminolysis in hypoxia and 




necessary to clarify this possible metabolic pathway using isotope-labeled glutamate in low 
glucose and hypoxia conditions. 
As we discussed above, claudin-7 is likely to perform multiple functions in regulating lung 
cancer cell progression based on our previous and current studies. Firstly, claudin-7 rather than β1 
integrin mainly modulates cell proliferation, migration, invasion, and attachment. Secondly, 
claudin-7 also alters glucose metabolism to support cancer cell survival in tumor 
microenvironments in vivo and in vitro. Despite the promising characteristics of elevated lung 
cancer metastatic potential on the claudin-7 KD of human lung cancer cells, our in vivo metastatic 
mouse tumor study did not show any metastatic nodules in lymph nodes or micrometastatic lesions 
in mouse tissues, including the lung and liver (Fig 1.2.). It has been reported that HCC827 parental 
lung cancer cells are of low metastatic potential (67). Thus, the low metastatic potential of HCC827 
lung cancer cells may be attributed to the failure to generate metastatic nodules in athymic nude 
mice. Conversely, claudin-7 KD may promote stages of cancer promotion and progression but not 
metastasis. Future in vivo experiments are needed to characterize the roles of claudin-7 KD using 
high metastatic human lung cancer cells in cancer progression.  
The concomitant reduction of β1 integrin upon claudin-7 KD in human lung cancer cells 
is thought to indicate increased lung cancer metastatic potential, including hyper-proliferation, cell 
detachment from the ECM, and β1 integrin reduction. In addition, a clinical research team has 
found a strong association between low claudin-7 expression of lung cancer patients and their low 
survival rate (35). However, it is not clearly understood how low claudin-7-expressing highly 
metastatic lung cancer cells can metastasize to secondary sites through blood circulation, although 
the ubiquitously present β1 integrin may not be highly present to support cell-matrix adhesion-




cytoskeleton to use friction as a mode of amoeboid cell migration when the cells pass through 
physically confined areas and non-adhesive environments in vitro (146). Likewise, human lung 
cancer cells could also metastasize by decreasing claudin-7 to abolish focal-adhesion-based 
migration in order to adapt fast amoeboid migration while they are circulating through blood 
vessels for lung cancer metastasis. 
In conclusion, we first report that a TJ protein, claudin-7, participates in multiple functions 
and modulates human lung cancer metastatic potential and carcinogenesis. Claudin-7 controls cell-
matrix adhesion that also regulates cell migration and invasion and the attachment of human lung 
cancer cells at the ECM surface for cancer metastasis. For cancer promotion and progression, 
claudin-7 adjusts cell proliferation to expedite lung tumor growth by altering cell metabolism for 
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